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Mechanical forces have become increasingly important for determining cell 
behavior and maintaining normal tissue physiology. Mis-regulation of mechanical forces 
has been implicated in fibrotic conditions in which the extracellular matrix of the diseased 
tissue is significantly less compliant compared to ECMs of healthy tissues. In the case of 
idiopathic pulmonary fibrosis (IPF), which affects 5 million people worldwide, the fibrotic 
regions are characterized by the accumulation of myofibroblasts - highly contractile cells 
which produce collagen and fibronectin at the leading edge of existing scars. Consequently, 
it is thought that abnormal myofibrolast contractility and excess matrix deposition are key 
drivers for fibrogenesis. Of particular interest is the ECM protein fibronectin, which can 
be assembled into fibers within the ECM and serve as the early provisional matrix in wound 
healing.  
 Fibronectin (Fn) has the potential to be an ECM mechanosensing protein. Both in 
silico and in vitro studies have indicated that Fn and its many type III repeats can be 
extended and partially unfolded under physiological forces. Indeed, it has been 
hypothesized that the unfolding/refolding phenomenon of Fn type III repeats may be a 
possible mechanism for relating mechanical forces in the extracellular environment to 
intracellular biochemical signals, through changes in the structure of Fn. It has been shown 
by our lab and others that conformational changes in Fn may potentially instruct cell 
behaviors through modulating interactions with cell surface receptors such as integrins. 
Additionally, altered Fn structure has been suggested to affect biochemical modifications 
to Fn, including enzymatic degradation and post-translational modifications. Current 
 xvii 
studies of Fn conformational change has been restricted to non-specific adhesion-and-
pulling experiments by atomic force microscopy (AFM), or studied via molecular dynamic 
simulations of Fn at short timescales. As a consequence, considerable debate has emerged 
regarding the physiological relevance of Fn conformational change in vivo, and it remains 
to be shown that Fn exists in different conformations in native ECMs.  
The governing hypothesis for this project was that conformational changes 
imparted to Fn by mechanical forces could alter presentation of molecular epitopes to cells, 
and that these changes could be exploited to develop molecular probes. Such probes may 
be useful for both fundamental studies of Fn-integrin mechanobiology as well as for 
molecular diagnostic imaging of fibrosis. This hypothesis was investigated with the 
following specific aims: 
 
Specific Aim 1: Investigate the role of fiber strain on conformational alterations of Fn 
fibers, and isolate strain-sensitive peptide probes by phage display.  
 
Native plasma Fn was purified and deposited into in vitro fibers on flexible 
patterned PDMS membranes. Uniaxial straining of the PDMS membrane (and thus 
straining of the immobilized Fn fibers) was shown to correlate with the solvent 
exposure of known buried cysteine residues, suggesting a correlation between fiber 
strain and conformational change of the 7th and 15th type III Fn repeats. Phage 
display and selection using a random peptide library was used to isolate phage 
clones that targeted to Fn fibers under relaxed and strained conditions.  
 
 xviii 
Specific Aim 2: Investigate conformational changes within the Fn III9-10 region 
through engineered Fn fragments, and isolate specific Fn fragment targeting 
antibodies by phage display.  
 
Engineered Fn fragments modeling the spatial orientation between the PHSRN and 
RGD sequences in the 9th and 10th Fn type III repeats was used as a model of force-
induced conformational changes to the central cell binding region of Fn. 
(Engineered fragments: FnIII9*10, FnIII9-4G-10). Specific scFv antibodies were isolated 
by phage display and selection on these Fn fragments. One specific antibody, the 
H5 clone, was found to preferentially bind the FnIII9-4G-10 fragment, and inhibited 
cell attachment through modulating specific Fn-αvβ3 integrin interactions. 
 
Specific Aim 3: Explore the utility of scFv antibodies for fibronectin targeting in 
diagnosis and monitoring of disease progression in mouse model of pulmonary 
fibrosis 
 
The H5 scFv antibody was evaluated for mechano-sensitive staining of Fn in 
multiple model systems. Using in vitro deposited Fn fibers, staining of H5 increased 
with increasing Fn fiber strain. In Fn within fibroblast assembled ECMs, H5 
staining patterns was capable of distinguishing specific Fn fibers within the matrix, 
and was enhanced by treatment of cells with the contractility promoter TGF-β. On 
lung tissues isolated from normal and from fibrotic mice, H5 staining was more 
pronounced on fibrotic lung tissue and showed distinct staining patterns. In a 
 xix 
minimally invasive live animal model, the H5 antibody targeted to and accumulated 






LITERATURE REVIEW  
Fibronectin 
Fibronectin (Fn) is widely considered to be a paradigm adhesion protein, and is 
involved in crucial cellular and physiological processes including development, wound 
healing, and cancer. 
Fn’s most widely explored function has been to confer adhesiveness of tissue 
culture surface to cells by adsorption or immobilization of Fn from solution onto tissue 
culture surfaces, and it is for this reason that Fn has been the focus of much research. 
Though Fn has been well studied for over three decades, many new activities of Fn are 
being revealed and much remains to be elucidated about the structure-function relationship 
of this glycoprotein, particularly with regards to the highly modular domain structure of 
Fn, with its many Fn type III repeats.  
  At the molecular scale, Fn is a dimer of two nearly identical ~250kDa subunits 
linked at their C-termini by a pair of disulfide bonds. Each monomer is structurally 
organized and composed predominantly of repeating modules termed type I, II, and III 
repeats(1). These distinct domains of Fn serve functional roles that mediate binding 
interactions between Fn to cell surface receptors, to other ECM components, as well as to 
Fn itself. The N-terminal type I repeats of Fn have been shown to be essential for Fn-Fn 
associations for Fn fibrillogenesis and matrix assembly. As evidence, recombinant Fn 
proteins lacking these domains do not assemble into matrices(1), and exogenous addition 
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of the amino-terminal 70kDa fragment of Fn (which contain these type I repeats) have been 
shown to disrupt and disassemble Fn matrices(2, 3).Type II repeats of Fn are less well 
understood, but are thought to be involved in binding to collagens and gelatin(4). Indeed, 
the gelatin binding property of Fn is often used to purify Fn from plasma, and homologs of 
Fn type II repeats have been found in many other ECM proteins that bind gelatin(5).  
Most interesting of all are the 15 to 17 Fn type III repeats that make up the majority 
of the protein. These Fn type III repeats are composed of seven antiparallel beta-strands 
that fit together to form a beta sandwich structure (6, 7). Fn type III domains are ubiquitous, 
found not only in Fn, but in an estimated 2% of all vertebrate proteins. This wide 
distribution of Fn type III domains in mammalian proteins suggested that Fn III domains 
are evolutionarily conserved and its unique structure may have conferred Fn type III repeats 
the flexibility to perform multiple functions. Unlike type I and II repeats, Fn type III repeats 
are not stabilized by intramolecular disulfide bonds (8). Consequently, the folded Fn type 
III repeats are stabilized only by non-covalent interactions and have been shown to be 
structurally flexible and even unfold under physiologically relevant forces (9-11).  
Considerable work in vitro and in silico have suggested that Fn type III domains 
can be unfolded with applied forces in the range of tens to hundreds of pN(11-15). 
Furthermore, different Fn type III domains were found to have a range of mechanical 
stabilities. Among the Fn III domains that make up the III7-10 central cell binding domain, 
molecular dynamic simulation results suggested that III10 required the lowest threshold of 
force to unfold, while III7 required the highest force (16). Both MD and AFM force 
spectroscopy data have also suggested that stable intermediate states of unfolding exist for 
Fn III10 domains(14, 16). Given that Fn III10 contains the RGD integrin binding motif 
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responsible for engaging a variety of integrin receptors on the cell surface, these results 
strongly implicate that mechanical perturbations of Fn III domains in the central cell 
binding domain can regulate biochemical events such as integrin engagement and affect 
cell processes such as adhesion and migration. Furthermore, the results inferred from III10 
may also apply to other Fn type III repeats. Indeed, experimental evidence from Erickson 
and coworkers(17) suggested that multiple Fn type III repeats can undergo domain opening 
and unfolding both as purified proteins in solution, as well as in assembled fibers in 
cultured ECMs.   
Evidence of Fn unfolding in vivo within native ECMs have not been reported, and 
controversy remains as to whether Fn unfolding events occur in vivo, or if the unfolding 
and extension of Fn observed in vitro were in fact re-orientation of the Fn molecules under 
force(18). However, it is generally accepted and appreciated conformational changes in Fn 
do occur and may have an important role in vivo for mediating Fn-protein interactions (19).  
  In vivo, Fn is found as both soluble dimeric plasma fibronectin (pFn) and 
crosslinked cellular fibronectin (cFn) constituting the Fn matrix found in many cellular 
microenvironments. Plasma Fn is synthesized and secreted by hepatocytes, whereas 
cellular Fn is produced primarily by fibroblasts and assembled into an organized fibrillar 
matrix in an integrin-mediated, cell-dependent manner. Additionally, circulating or 
exogenously added plasma fibronectin can also be crosslinked into this matrix (20). Plasma 
and cellular Fn differ in their domain composition, and arise due to alternative splicing of 
a precursor Fn mRNA transcript that can generate a number of Fn variants(21-23). Splicing 
can occur in the variable (V) region that connects III14 and III15, but also in 
inclusion/exclusion of specific Fn type III domains. Of all the Fn type III domains in human 
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Fn, 15 are constitutively included, and 2 are alternative spliced. These two are termed 
“extra” domains, or EDA and EDB domains. Plasma Fn produced by hepatocytes contains 
very little to no EDA and EDB domains, whereas Fn synthesized by other cell types are 
much more heterogeneous, and the inclusion of EDA and EDB domains is cell type 
specific. Functionally, Fn containing EDA is found at higher levels in tissues where the 
cells are actively migrating: such as during embryonic development, wound healing, or 
surrounding tumors (24). The presence of EDA is thought to destabilize adjacent Fn type 
III domains, reducing the forces needed to unfold them (25, 26). This may be yet another 
mechanism by which mechanic forces can affect the structure of Fn and alters its protein 
binding activities.  
 Integrins are the most well studied receptors for Fn. Integrins are heterodimeric 
cell surface receptors that link the ECM to the cytoskeleton, with as many as 12 distinct 
integrins having been shown to be capable of ligating to Fn (27). The classical Fn integrin 
is integrin α5β1, and binds to the RGD recognition motif in III10 - this is one of the most 
well studied Fn-integrin interactions. The interaction between integrin α5β1 and RGD is 
also dependent on the adjacent PHSRN “synergy” site in III9, which greatly enhances 
binding of α5β1 to Fn, presumably by binding to the α5 subunit and altering its 
conformation. Other integrins, such as αvβ3, α4β1, and α4β7 also bind to Fn at specific 
recognition sites(1).   
In addition to integrins, Fn can also bind a variety of extracellular ligands: including 
fibrin(4), collagens and gelatin(4), heparin(28), and tenascins(29, 30). More recently, 
binding sites for heparin sulfate and growth factors such HGF and VEGF have also been 
found(31). Even many bacterial proteins target Fn as a method to attach to and colonize 
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their hosts (32, 33). This large number of protein binding partners has prompted 
investigators to hypothesize that perhaps with its modular structure rich in binding sites, 
Fn can regulate the distribution, activation, and presentation of growth factors and proteins 
to cells(31). This fundamentally changes the view that Fn, and indeed the ECM as a whole 
as passive scaffolds, and instead supports the view that ECMs can actively guide and direct 
cellular processes. In this new paradigm, the role of mechanical forces and Fn 
conformational changes becomes ever more important. Mechanical forces can allow for 
dynamic regulation of cell-ECM interactions, a concept supported by the  many binding 
sites in Fn type III domains that have been characterized as so called “cryptic” binding 
sites(34-36), in which binding of the protein of interest only occurs under unfolded or 
conformationally open conditions.  
Fn also contains a number of enzymatically active regions and can undergo a 
number of post-translational modifications, the extent of which is different for Fn in 
different tissue and in different environments. The list of PTMs to Fn include 
phosphorylation, sulfation, acylation, and glycosylation. The significance of these 
modifications is not well known, but it has been observed that Fn from cultured cells 
contain much less sugar content than Fn from embryonic fibroblasts(4). Both plasma and 
cell derived Fn can be enzymatically digested by tPA, urokinase, and other matrix 
metalloproteinases(37). Though these digestion sites have been largely determined (38), it 
is unclear whether enzymatic digestion of Fn is dependent on Fn conformation state. 
However, it is reasonable to hypothesize that Fn conformational changes may play a role, 
as MMP mediated degradation of the Fn matrix is thought of as an early event in malignant 
transformation, where cells are actively exerting contractility forces on their ECMs.  
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Integrins 
 Integrins comprise a family of heterodimeric transmembrane receptors that link the 
cell cytoskeleton to the ECM(27). The name for the integrin family of receptors was termed 
to describe this structurally related family of receptors for their function in integrating the 
extracellular matrix proteins with the cytoskeleton for mediating cell migration and 
adhesion. Currently, 8 distinct integrin β subunits, and 18 distinct integrin α subunits have 
been discovered. Together, 24 distinct integrin receptors have been observed to form from 
the noncovalent association of α and β subunits(39).  
 A considerable body of literature exists that describe the structural biology of 
integrin receptors(40, 41), including requirements for divalent cation binding(27), 
intracellular signaling events that mediating integrin inside-out-signaling(42-44), and 
conformational changes that results in switching from the low-affinity to high affinity 
conformations(45, 46).  
 Integrins play a critical role in the assembly of Fn into fibrils within the ECM(47). 
As evidence, Fn matrix assembly is integrin dependent, and cells lacking the α5 and αV 
integrin subunits fail to assemble Fn into fibrils, even though the protein is still secreted 
normally by the cells(48). Though many integrins can bind to Fn, integrin α5β1 is the major 
Fn integrin that cells use to engage and assemble Fn molecules into the matrix (49, 50). 
The two most well studied Fn integrins, α5β1 and αvβ3, both engage the RGD site within 
the 10th Fn type III repeat. Integrin α5β1, however, can simultaneously engage both the 
RGD and the PHSRN (“synergy”) site in the 9th Fn type III repeat for high-affinity Fn-
integrin interactions(51). Furthermore, recent evidence suggested that integrins α5β1 and 
αvβ3 can work together to optimize fibroblast rigidity sensing on a Fn-based substrate (52), 
and may have implications for cell migration and invasion in fibrotic pathologies and 
cancer.  
Thus, investigators have hypothesized that alterations in the molecular spacing between 
the RGD and PHSRN sites may result in an integrin “switch” in which force-actuated 
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changes to molecular conformations of the FnIII9-10 region can result in differential 
integrin engagement and possibly mediate different signaling events. Such a mechanism, 
if confirmed, could offer a powerful tool for researchers to engineer integrin-specific cell 
response by control of the ECM for tissue engineering and regenerative medicine 
applications(53). Evidence of this integrin switch has not been demonstrated in vivo, due 
to the lack of appropriate molecular probes.  
 
Phage Display 
 Phage display is a technique whereby functional motifs are presented at the surface 
of bacteriophage coat proteins by fusion to the viral coat protein genes (54, 55). These 
functional motifs are most often peptides or single chain antibodies, but other forms of 
display technologies are also possible (56-58).  
 The power of phage display is realized from the generation of large libraries of 
phage displayed peptides or antibodies and the ability to link the displayed motif with the 
genotype. Conceptually, this library can then be screened against a target molecule to 
isolate specific binding motifs, without a priori knowledge of the binding site structure or 
sequence. Randomization of the peptide or antibody repertoire occurs at the genetic level, 
whereby random oligonucleotides can be generated by PCR and ligated into vectors. 
Design of the random oligonucleotide library can be fully degenerated, where all 20 amino 
acids are represented equally, or biased towards a specific subset of amino acid by 
randomizing at only certain positions in the codon triplet (56). It may be desirable to avoid 
certain amino acids, or avoid certain stop codons when expressed in microorganism hosts. 
After the generation of a random oligonucleotide library, these random fragments are then 
ligated into digested vectors and transformed into competent E. Coli. cells. The diversity, 
or different number of possible displayed peptides, is determined by the length and manner 
of randomization (ie. a fully degenerate 10-mer library will have a diversity of 210 different 
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peptides). However, this can be limited by the transformation efficiency of host cells. For 
E. Coli, this is usually limited to 109 transformants per 1ug of DNA (56).  
 Phage display screening procedures consists of repetitive cycles of incubation with 
the target, extensive washing, elution of bound phage particles, and amplification of 
recovered phage (59-61). After 3 to 5 rounds of panning, the pool of recovered phage is 
enriched for binders that target the antigen of interest. Individual clones from this pool can 
then be isolated, sequenced, and assayed for their ability to bind the target.  
 Phage display biopannings have previously been applied to Fn, where work by 
Ruoslahti and coworkers(62) used phage display to isolate a cyclic peptide that mimics the 
binding of β1 and β3 integrins to Fn. Much remains to be explored about the potential for 
using phage display to isolate Fn targeting peptides and antibodies, especially with regard 
to conformation specific peptides and antibodies. As part of this thesis, I will use phage 
display to isolate molecular probes that target both Fn fibers under varying mechanical 
strain, as well as single molecules of Fn fragments spanning the 9-10th type III repeats 
engineered to model molecular tension in the Fn molecule.  
 
Pulmonary fibrosis 
 Tissue fibrosis is characterized by excess extracellular matrix (ECM) deposition 
and is associated with scarring and impairment of tissue function. In the case of idiopathic 
pulmonary fibrosis (IPF), a disease of unknown pathogenesis and no current cures (63), 
early diagnosis and monitoring may offer significant patient benefits. The pathogenesis of 
IPF in humans is not known, but is thought to involve cellular changes to alveolar epithelial 
cells (AEC) that may result from abnormal wound healing responses in the lung(64). It is 
thought that type I AEC, which normally serves to keep interstitial mesenchymal cells in a 
state of homeostasis through secretion of soluble factors, can be injured or lost. Type II 
AECs are then thought to proliferate and occupy spaces previously occupied by type I 
AECs. However, in normal wound healing, these type II AECs undergo regulated apoptosis 
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and remaining type II AECs differentiate to become type I AECs. In pathological 
conditions, this does not occur and fibroblasts (especially α-SMA expressing 
myofibroblast) instead accumulate in these damaged regions and secrete large amounts of 
ECM proteins. These large regions of scar tissue and fibroblasts are termed “fibroblastic 
foci” and is a characteristic marker of the disease.  
 There is currently no cure for IPF other than a lung transplant. However, treatment 
options exists that can help manage comorbidities associated with IPF, as well as 
investigational therapies that may help slow the progression of fibrosis. These include anti-
inflammatory and immunomodulatory agents such as corticosteroids, antioxidant agents 
such as N-acetylcysteine, cytokines such as interferon-γ(63), and cell contractility 
inhibitors such as fasodil(65), among others.    
 The mechanics of the ECM is an underexplored area with regards to the 
pathophysiology and potential therapies for pulmonary fibrosis. Recent investigations, 
however, have suggested that reduced lung compliance is associated with increased 
integrin α5β1 mediated Fn deposition and basement membrane matrix assembly(66). 
Furthermore, our lab has shown that fibrotic lung ECM is significantly stiffer compared to 
normal ECM, using atomic force spectroscopy (67). Thus, it is hypothesized that the 
mechanical changes to the Fn matrix may be a molecular signature for progression of the 
disease.   
 Due to the severity of IPF, early detection and disease management, including 
monitoring of fibrosis progression, could offer significant patient benefits. To this end, 
non-invasive imaging of IPF has become an active area of research, with recent reports of 
collagen targeted MRI probes(68) as well as optical probes that are cleavable by specific 
MMPs upregulated in a mouse model of IPF(69). In this work, we take a similar inspiration 
in developing ECM targeting probes to detect biophysical changes to Fn that may occur in 
fibrotic ECMs. 
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 CHAPTER 2 
REAGENTS AND EQUIPMENT 
Antibodies and reactive dyes 
 Alexa Fluor 488 TFP ester, Alexa Fluor 633 SE, and Alexa Fluor 546 C5 maleimide 
dyes were purchased from Invitrogen (Life Technologies, Grand Island, NY). Alexa Fluor 
488 goat anti-rabbit, Alexa Fluor 546 goat anti-mouse, Alexa Fluor 546 streptavidin, 
quantum dots Qdot 585, and Qdot 705 antibody labeling kits were purchased from 
Invitrogen (Life Technologies, Grand Island, NY).Peptides were produced by solid phase 
synthesis (Genscript, Piscataway, NJ). Anti-myc antibody was purchased from Invitrogen 
(Life Technologies, Grand Island, NY).  Biotinylated anti-Myc antibody and biotinylated 
anti-M13 antibody were purchased from Sigma (St. Louis, MO). Rabbit anti-rat Fn 
antibody was purchased from Millipore (Billerica, MA). Anti-beta1 integrin antibody was 
obtained from developmental studies hybridoma bank (AIIb2 clone, Univ of Iowa). 
Antibodies for flow cytometry were the following: anti-integrin α2 (10G11 clone, 
Millipore, Billerica, MA), anti-integrin α3 (ralph 3.2 clone, Santa Cruz Biotechnology Inc, 
Dallas, TX), anti-integrin α5 (P1D6 clone, Millipore, Billerica, MA), anti-integrin α6 
(NKl-GoH3 clone, Millipore, Billerica, MA), anti-integrin α8 (F-11 clone, Santa Cruz 
Biotechnology Inc, Dallas, TX), anti-integrin αVβ3(LM609 clone, Millipore, Billerica, 
MA), anti-integrin β1 (TS2/16 clone, Biolegend, San Diego, CA).  
 
Cell culture 
 Tg1 and HB2151 E. Coli cells were obtained from Geneservice (SourceBioScience, 
United Kingdom). Mouse primary lung fibroblasts, human foreskin fibroblasts, K562 cells, 
CHO-B2 and integrin αvβ3 transfected CHO-B2 cells were kindly provided from Vince 
Fiore (BME, GaTech). H69 cells were kindly provided by Dr. Ashely Brown (BME, 
GaTech).   Primary lung fibroblast, and HF were maintained in growth medium of DMEM, 
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10% FBS, and 1% penicillin/streptomycin. CHOB2, and CHOB2- αvβ3 cells were 
maintained in DMEM, 10% FBS, 1% non-essential amino acids, and 1% 
penicillin/streptomycin. H69 cells were maintained in RPMI 1640 medium, with 10% FBS, 
and 1% penicillin/streptomycin. K562 cells were maintained in RPMI 1640 medium, with 
10% FBS, 1% non-essential amino acids, and 1% penicillin/streptomycin. All cells were 
cultures in 37°C incubator, with 5% CO2 atmosphere.  
 
Animal model 
 Mice (female, C57/Bl6, 8 weeks old) were obtained from Charles River 
Laboratories (Wilmington, MA) and were house for one week prior to bleomycin injection. 
All procedures were performed in accordance to Georgia Tech IACUC protocol (A12079).  
 
Protein purification 
 Recombinant protein production and scFv antibody purification was performed on 
an AKTAFPLC liquid chromatography system (GE Lifescience, Pittsburg, PA). For 
recombinant protein purification, lysed product was filtered and run on a GST column 
(HiTrap GSTPrep, GE Lifescience, Pittsburg, PA), followed by thrombin digestions 
overnight to cleave GST tag, and purified fragments were separated from cleaved products 
by purification with GST column in series with Benzamidine column (HiTrap Benzamidine 
FF, GE Lifescience). For scFv antibody purification, filtered cell culture medium 
containing scFv antibody were pumped by a sample pump (P960) over a HiTrap ProteinA 
column (GE Lifescience, Pittsburg, PA) and elution using 200mM glycine, pH 2.5 buffer.  
 
SPR 
 SPR experiments were performed on a BIACORE 2000 instrument (GE 
Lifesciences, Pittsburg, PA). Buffers used were the following: Immobilization buffer 
(0.1M sodium acetate, pH 4.5), quenching buffer: 1M ethanolamine, pH 9, binding buffer 
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(10mM HEPES, 150mM NaCl, 0.0001% Triton-X 100, pH 7.4, regeneration buffer (20mM 
EDTA, 1M NaCl, pH 6).  SPR binding experiments were done using kinetic injections at 
30µL/min, with a 10min dissociation time. Regeneration of surface was performed using 
two injections of 5µL each of regeneration buffer. SPR sensograms were processed with 
Scrubber2 software for double referencing, and curves were fit to experimental data using 
a 2-site heterogeneous surface model using ClampXP software.    
 
Microscopy 
 Widefield fluorescence microscopy was performed on a Nikon Eclipse Ti 
microscope, with epifluorescence illumination and standard DAPI/FITC/TRITC filter sets. 
Confocal fluorescence microscopy was performed using a Zeiss LSM 510 NLO w/ META 
MPE confocal microscope, using excitation lasers at 488nm, 545nm, and 633nm.  
 
In vivo imaging 
 In vivo imaging in mice was performed on two small animal bioimaging systems. 
Preliminary IVIS images were acquired using Xenogen Lumina® imaging system using 
the following parameters: excitation: 745nm, emission, 780nm, exposure 10 seconds, 
medium binning, field stop: 2, stage position C. FMT images were acquired with 
fluorescence efficiencies corrections.  
 Monitoring of fibrosis progression and time course imaging with the H5 antibody 
was performed with fluorescence molecular tomography (FMT). Mice were imaged on a 
FMT 2000 fluorescence tomography system (Perkin Elmer) with 745nm laser excitation. 




SPECIFIC PHAGE DISPLAYED PEPTIDES COULD BE 
DEVELOPED TO TARGET FN FIBERS OF VARYING STRAIN 
 
 We began to explore Fn conformational changes by starting our investigation using 
Fn in the form of fibers, specifically in vitro fibers deposited from plasma Fn. This 
approach has the advantages of ease of generation of Fn fibers of defined strain, as well as 
previously published reports (70, 71) suggesting that applying strain to these in vitro Fn 
fibers could result in conformational changes of Fn molecules within the Fn and 
concomitant unfolding of Fn type III repeats. In addition, incorporation of a small 
percentage of fluorescently labeled Fn molecules within the deposited Fn fibers allowed 
for facile imaging of the Fn fibers. Thus, using Fn fibers of varying strain, we sought to 
ask if mechanical straining of the fibers could result in altered presentation of molecular 
epitopes on the surface of the Fn fibers, and if molecular probes in the form of phage-
displayed peptides could be generated against these Fn fibers of varying strain. In this 
chapter, we aimed to develop a platform technology to perform high throughput screening 
on Fn fibers of varying mechanical strain. Our intended application was to develop imaging 
probes targeted to Fn fibers (discussed in Chapter 6), but this approach could be adapted 




  Fn molecules within fibers of native ECMs are thought to adopt a range of 
conformations induced by applied forces (Figure 1a). In order to realize the goal of 
identifying strain-selective probes to Fn fibers, methods are needed for highly reproducible 
and controlled mechanical straining of pure Fn fibers. To this end, we manually extruded 
Fn fibers onto flexible PDMS membranes and aligned them perpendicular to the long axis 
Figure 1. Integrated system for identifying conformation sensitive molecular probes for Fn fibers. A) 
Schematic for single Fn fibers in native ECM under different mechanical environments. Left, a relaxed Fn 
fiber. Right, a strained Fn fiber under loading of the ECM in the longitudinal direction. B) (1) Fn fibers were 
deposited onto chemically treated, patterned PDMS surfaces. (2) PDMS with Fn fibers were then strained 
using a homemade PDMS straining device capable of applying strain of up to 300%. (3)Schematic of freely 
suspended Fn fibers on relaxed (left) and strained (right) patterned PDMS substrates on which phage panning 
were performed to identify, strain specific probes for Fn fibers. 
 
 15 
of micropatterned plateau/trough structures as previously described with minor 
modifications (72-74).  Subsequent crosslinking of Fn fibers to the PDMS allowed for the 
suspension and controlled straining of fibers using a uniaxial mechanical straining device 
(Figure 1b steps 1, 2).  The second element of our strategy consisted of applying a random 
phage display library to interrogate the Fn fiber surface (Figure 1b, step 3).  Strained or 
relaxed fibers were placed in a holding chamber to enable phage incubation under 
controlled conditions.  The phage enrichment process followed a typical workflow starting 
with a randomized library (1012 clones of 6.4x107 diversity). 
 
Materials and Methods 
Purification of Fn from plasma and fluorescent labeling 
 Fibronectin was purified from frozen pooled human plasma (Red Cross, 
Douglasville, GA) following a gelatin affinity chromatography protocol (75). Frozen 
plasma aliquots were thawed in a 37°C water bath, and residual red cells were removed by 
centrifugation. Phenylmethylsulfonyl fluoride (PMSF) was added to inhibit serine 
proteases, and plasma was then filtered over a packed Sepharose 4B column (GE 
lifesciences, Pittsburg, PA), then over a packed Gelatin Sepharose column (GE 
lifesciences, Pittsburg, PA). Bound Fn was eluted from the column by 6M urea, and 
refolded by dialysis into PBS overnight at 4°C. Purified Fn was verified by SDS-PAGE 
and western blotting against Fn. Labeling of purified Fn with Alexa Fluor 488 was done 
by addition of 10% by volume of 1M sodium bicarbonate (pH 9) to Fn in PBS, then reaction 
with 20X molar excess of Alexa Fluor 488 TFP ester for 1 hour at room temperature. 
Unreacted dye was removed by overnight dialysis into PBS at 4°C. For Fn fiber deposition, 
labeled Fn was mixed with unlabeled Fn in 5-95 (w/w) ratios, at a final concentration of 
1mg/mL.  
 
Fn fiber deposition: 
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 Substrates for Fn fiber deposition were prepared on PDMS by soft lithography, 
features were 10m by 100m ridges, separated by 50m spacing. Masks were designed 
in CAD software and silicon masters were fabricated using standard photolithography. Fn 
was purified from frozen human plasma by gelatin-sepharose affinity chromatography. Fn 
fibers were deposited on PDMS from 1mg/mL concentrated solutions as previously 
described (73, 74). For phage display panning, the deposited fibers were allowed to air dry, 
and non-fibrillar Fn spots were blocked with 2mg/mL gelatin. The substrate was then 
blocked with 10mg/mL BSA for 1 hour, strained to defined amounts using a homemade 
straining device (Figure 1b), and a holding chamber was formed with cloning cylinders 
(6mm diameter, Corning, Corning, NY) for incubation for phage or antibodies.  
 
Phage display panning: 
Fuse5 6-mer phage library on Fn fibers: 
 A negative screen was first performed with BSA and gelatin-blocked PDMS. An 
aliquot containing 1011 phage from the fuse5 6-mer library (gift from Dr. George Smith, 
Univ of Missouri, Columbia, MO) was incubated for 1 hour on the blocked PDMS, with 
gentle shaking. Supernatant phage were collected and amplified by infection of 10mL of 
starved Tg1 E.Coli. cells and grown overnight in LB broth, 15g/mL tetracycline, and 
1mM IPTG. Phage particles were precipitated from overnight cultures by first centrifuging 
the cultures at 10,800g for 15 min then adding 15% (by volume) 3.3M NaCl and 25% w/v 
PEG 8000 to the culture supernatant. After overnight precipitation at 4C, the solution was 
centrifuged at 6000g for 45 min and the phage pellet was resuspended in PBS. Phage 
physical concentration was determined using UV/Vis spectroscopy (CFU/mL = (A269nm-
A320nm)/9225 x 6 x10
17)and 1x1011 phage particles were used as the input for first round of 
positive selection. Phage were allowed to incubate on deposited Fn fibers for 1 hour, 
followed by incubation with wash buffer (PBS, 0.05% tween-20) for 10 min, and eluted 
with 0.2M glycine, pH 2.1, and neutralized with 1M Tris-HCl, pH 9. Eluted phage were 
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propagated into Tg1 cells, and purified as above. Three rounds of selection were performed 
in parallel on both relaxed and strained Fn fibers. Stringency of selection was controlled 
by subsequently increasing the number of wash steps prior to phage elution for each 






Figure 2. Cysteine exposure within III7 and III15 correlate with Fn fiber strain. A thiol-reactive 
compound (AlexaFluor 546-maleimide) was used to detect the unmasking of the buried free cysteine residues 
in FnIII7 and FnIII15. Images were acquired at 63X, shown is normalized intensity of AF546 channel divided 




Straining of Fn fibers immobilized on PDMS exposes buried cys in FnIII7 and FnIII15 
As a first step to establish that mechanical straining of Fn fibers in vitro can result 
in measurable conformational changes in Fn type III repeats, and to validate our 
experimental system for Fn fiber straining - we followed an assay to detect the exposure of 
buried cysteine residues within 7th and 15th Fn type III repeats. Using a uniaxial straining 
device we were able to apply tension to the patterned PDMS substrate and achieve strains 
of the deposited Fn fibers exceeding 260% without significant breaking of Fn fibers. 
Because the Fn fibers were crosslinked to the underlying PDMS substrate, strain applied 
to the PDMS will be equivalent to the strain applied to the Fn fibers.   
 We quantified the exposure of cryptic cysteine residues in 7th and 15th type III 
domains using a modified cysteine shotgun method(76). We observed increasing exposure 
of the buried cysteine residues with increasing Fn fiber strain (Figure 2). Normalized 
images of the reporter dye to total amount of Fn displayed increasing thiol-reactive reporter 
dye binding with increasing strain of the PDMS (top to bottom).  Analysis of at least 25 Fn 
fibers displayed a robust and linear (r2=0.63) relationship between Fn fiber strain and 
exposure of cryptic cysteine residues.  We note that it is likely for other domains of Fn in 
addition to III7 and III15 to also be partially unfolded as a result of the applied macroscopic 
strain, as literature reports suggests that III7 is among the strongest Fn type III repeats in 
terms of structural stability, while III10 is among the weakest(16).  
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  Table 1. Sequences of isolated phage following 
selection on Fn fibers. Clones were sequenced after 3 
rounds of panning. 
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Isolation of specific phage clones targeting Fn fibers under varying strain 
 We performed phage display pannings to identify unique peptides that discriminate 
Fn fibers under varying strain, specifically a ‘relaxed’ and a ‘strained’ state. The fuse5 6-
mer phage peptide library was chosen because the random peptides are fused to the pIII 
coat proteins, located at the tip of the phage, and are therefore thought to be sterically 
favorable to probing unfolded domains.  Furthermore, the relatively low number of copies 
of pIII per phage makes multivalent binding less likely and as a result yields higher affinity 
interactions.  Our panning strategy involved an initial negative selection step to remove 
phage clones that bound to other targets besides Fn fibers, specifically gelatin and serum 
albumin. Supernatant phages (i.e., unbound phage) from this negative selection were then 
Figure 3. Enrichment of a population of phage binding to Fn fibers following 3 
rounds of phage panning on Fn fibers. A) Negative selection round to deplete 
library of nonspecific binders to surface. B-D) 3 successive rounds of panning, with 
stringency of binding controlled by number of wash incubations. 
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amplified and used for the round one of positive selection. Positive selection was 
performed on both ‘relaxed’ (extension ratio = 1.0;  =  / L) and ‘strained’ ( = 2.6) Fn 
fibers.  After each round of selection, all phages were collected and accounted for by phage 
titers, ensuring enrichment of a population of phage that bound strongly to the Fn fibers 
under each condition (Figure 3). After a total of three rounds of positive selection, each 
with increasing stringency, phage clones were isolated from individual Tg1 E. Coli. 
colonies and phage DNA was sequenced (Table 1). Translated sequences revealed multiple 
identical sequences recovered from different colonies, suggesting enrichment of selective 
sequences from the initial repertoire of random peptides. No clear homology was identified 
comparing sequences within each population (derived from relaxed or strained fibers). 
However, considering the short length of the randomized peptide sequence and the 




Eight of the identified phage clones were then individually produced and purified, and their 
binding to Fn fibers characterized by standard phage titer counts (Figure 4).  
 
Five clones of the 8 tested displayed significant (>107 CFU) and strain-selective binding 
to Fn fibers. Of particular interest were the clones displaying peptide sequences LNLPHG 
and RFSAFY. These two phage clones showed the greatest binding to Fn fibers and the 
greatest efficiency in discriminating between relaxed and strained Fn fibers.  The clone 
RFSAFY preferentially bound to strained fibers over relaxed fibers (3.1x107 CFU 
compared to 1.4x106 CFU, or a selectivity of 22.1) whereas clone LNLPHG preferentially 
bound relaxed fibers over strained fibers (1.4x107 CFU compared to 1.8x106 CFU, or a 
selectivity of 7.8). Clones displaying SRWYRI and ARERFY peptides showed good 
discrimination between relaxed and strained fibers (both binding relaxed), but their overall 
Figure 4. Binding of phage clones to Fn fibers of low and high strain. Eight clones were 
individually assayed for their binding to Fn fibers. 1 X 1011 phage were used per experiment. 
Control phage was phage population after round 3 of panning 
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binding efficiency to Fn fibers was significantly lower.  The only other clone that displayed 
significant binding to Fn fibers was GSNSKY, which bound preferentially to relaxed fibers 
(1.5x107 CFU) but had greater variability, as evidenced by the standard error of repeated 
titer counts.  Based on these observations, clones LNLPHG and RFSAFY were chosen for 
competitive binding assays with their corresponding soluble peptides (Figure 5).Binding 
of each phage clone to its antigen (LNLPHG to relaxed Fn fibers (A), RFSAFY to strained 
Fn fibers (B)) was found to be inhibited in a dose-dependent manner when co-incubated 
with its corresponding soluble peptide, indicative of peptide-mediated binding and not 
Figure 5. Competitive binding of phage clones with corresponding soluble peptides on Fn fibers of 
low and high strain. Two phage clones that show the greatest dynamic range in difference between 
binding closed compact (top, LNLPHG phage) and partially unfolded (bottom, RFSAFY phage) Fn fibers 
were characterized for their binding specificity. Each phage clone was co-incubated with its corresponding 
displayed peptide at increasing concentrations. Data was fitted using a nonlinear log(inhibitor) vs. 
normalized response fit and IC50 values were calculated to 0.55 µM for LNLPHG-phage, and 0.41 µM for 
RFSAFY-phage. N > 3 for all samples, error bars are SEM, Statistics were performed using a one-way 
ANOVA with Bonferroni post-test correction. (**, p<0.01) 
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nonspecific phage-related effects.  Calculation of the IC50 from the competitive binding 
data indicates nanomolar IC50 for both LNLPHG- and RFSAFY-antigen interactions (550 
nM and 410 nM, respectively).  Furthermore, inhibition was not observed when phage 
clones were incubated with scrambled versions of the peptides at 100 M concentration 
(Figure 6), demonstrating specificity of the interactions. Binding of the LNLPHG phage 
clone to relaxed Fn fibers, and of the RFSAFY phage clone to Fn fibers were found to be 
reversible (Figure 7), whereby strain application after phage incubation can displace bound 
phage from Fn fibers.    
 
Discussions and Conclusion 
 
Figure 6. Scrambled peptides do not inhibit phage binding to Fn fibers Phage clones displaying either 
the LNLPHG or RFSAFY peptide were incubated with its corresponding peptide or a scrambled peptide 
(HLNPGL or AYSRFF) at 100 M in the presence of relaxed ( = 0.93) or strained ( = 2.64) Fn fibers, 
respectively. Incubation with 100 M peptide that matched the phage-displayed peptide showed competitive 
inhibition (labeled “100”), whereas incubation with scrambled peptides did not (labeled “100, S”). N > 3 for 
all samples, error bars are SEM, Statistics were performed using a one-way ANOVA with Bonferroni post-




In developing a platform to interrogate the mechanics of Fn fibers, we discovered 
that indeed Fn fibers of varying strain present molecular epitopes in the form of alterations 
in the conformations of specific Fn type III repeats, observable by monitoring exposure of 
known buried cysteine residues. Furthermore, we showed that these biophysical changes 
to Fn fibers could be exploited to develop targeting agents using molecular evolution 
techniques such as peptide phage display. Using such an approach, we isolated two phage-
peptide probes displaying the LNLPHG and RFSAFY peptides, that bound relaxed 
(λ=0.93) and strained (λ=2.6) Fn fibers, respectively. Furthermore, we demonstrate that 
specificity and reversibility of the peptide mediated interactions, and showed that soluble 
peptides could effectively inhibit binding of the phage-peptide probes to their 
corresponding targeted Fn fibers.  
 However, these peptide based probes have a number of important limitations. 
Indeed, as our later imaging characterization showed, the relatively low binding affinities 
of these peptide based probes limit their usefulness in fluorescent imaging applications. 
More importantly, we recognize that the molecular surface of Fn fibers are heterogeneous 
and not well defined. As such, the binding epitopes of the peptide-based probes are 
unknown. To address these issues, we next sought to engineer a better defined system to 
Figure 7. Reversibility of phage binding. A) LNLPHG Phage (1e12 CFU) was incubated on relaxed Fn 
fibers (λ=0.93) for 30mins, fibers were then strained to λ=2.6 and phages were recovered and quantitated by 
titers. B) RFSAFY Phage (1e12 CFU) was incubated on strained Fn fibers (λ=2.6) for 30mins, fibers were 
then relaxed to λ=1 and phages were recovered and quantitated by titers. C) control phage (1e12 CFU) 
incubated on Fn fibers, and recovered after strain application. (statistics performed using t-test, 2 tailed *, 
p<0.05, ***, p<0.001) 
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investigate Fn conformational change in a force-sensitive region of Fn, and employed 
antibody phage display and selection methods to isolate high affinity binding antibodies to 
our model proteins. 
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 CHAPTER 4 
DEVELOPMENT OF ANTIBODIES THAT TARGET MOLECULAR-
STRAIN WITHIN THE FNIII9-10 REGION 
 
 The central cell binding domain of Fn spans the 7th through 10th Fn type III repeats, 
and is perhaps the most biologically active portion of the molecule in terms of engaging 
integrin receptors and mediating cell-ECM adhesions. Indeed, the RGD peptide sequence 
is derived from the 10th Fn type III repeat(77), and is perhaps the most widely used peptide 
sequence to confer adhesiveness to implanted biomaterials(78) and for targeted delivery of 
cargo to specific integrin-expressing cells(79). 
 The central cell binding domain of Fn is also exquisitely sensitive to conformational 
perturbations resulting from mechanical forces exerted by cells on the ECM. Reports 
suggested that the relative separation distance between the “synergy” PHSRN sequence in 
the 9th Fn type III repeat and the RGD site in the 10th Fn type III repeat is critical for 
engagement and activation of integrin α5β1(80). Indeed, a synthetic peptide-amphiphile 
consisting of the sequence PHSRN-(SG)5-RGD, in which the PHSRN and RGD sites were 
separated by 3.7nm, has been shown to  specifically engage integrin α5β1(81) and promote 
robust cell adhesion and spreading(82). This peptide, termed the PR_b peptide, has similar 
bioactivity as full length Fn in in vitro cell adhesion assays (82-84), and has been used as 
a targeting motif in functionalizing liposomes and other carriers for targeted delivery drug 
and gene delivery both in vitro(85, 86) and in vivo(87, 88).  
 These observations led us to hypothesize that force-induced alterations in the 
conformational state of the FnIII9-10 region may serve as a mechanosensor and “integrin 
switch” – that is, differential integrin engagement of Fn may result from conformationally 
alteration to integrin binding domains of Fn. This differential integrin engagement may 
then mediate different cell signaling events and perhaps alter cell phenotypes. Developing 
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antibody based probes to detect these conformational changes in the integrin binding 
FnIII9-10 region was thus the aim of this chapter.  
 
Experimental Design 
 We sought to take a similar approach as our earlier work of phage-peptide probes 
developed on Fn fibers of varying strain. First, we engineered two Fn fragments spanning 
the FnIII9-10 region (Figure 8), one fragment was a stabilized fragment (Leu
1408Pro 
mutation) mimicking the native active FnIII9-10 conformation (80, 89), while the second 
fragment introduced 4 glycine insertion mutations in the linker region between III9 and 
III10. These insertion mutations were created to model the increase in separation distance 
between PHSRN and RGD that could result from force-induced conformational changes 
to the central cell binding domain of Fn. Next, we performed phage display pannings using 
antibody libraries, and isolated human single fold antibodies (scFv) that were capable of 
Figure 8. Structural models of recombinant Fn fragments mimicking molecular strain. 
(top) stabilized 9*10 mutant, (bottom) 4 glycine insertion mutant. Molecular visualization was 
performed in PyMol software, 4 glycine insertion was assumed to adopt alp 
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distinguishing the two model Fn fragments in an ELISA assay. Purified antibodies were 
quantified to their binding affinities to the two model Fn fragments by SPR. Finally, we 
characterized the ability of one particular antibody clone (H5) for the ability to selectively 
modulate Fn-integrin interactions, using cell attachment assays with engineered cell lines 
expressing specific integrin receptors. 
 
Materials and Methods 
Cloning and production of Fn fragments 
Fn DNA was isolated from pFH154 plasmid (ATCC, Manassas, VA), and PCR 
amplification of Fn fragments spanning specific FnIII repeats was performed with 
following primers:  









Reverse primers:  
(5) FnIII9:5’AGTCGCGGCCGCCTAGCATGTTGATTGTTGGCCAATCA-3’,  
(6) FnIII11: 5’-AGTC GCGGCCGCCTAGCAGGTTACTGCAGTCTGAACCAGA-3’, 
(7) FnIII14: 5’-AGTCGCGGCCGCCTAGCACGAGCATTGTCATTCAAGGT-3’. 
Cloning vector pGEX4T-1 (GE Lifesciences, Pittsburg, PA) was digested with Sal1 and 
Not1 restriction enzymes (New England Biolabs, Ipswich, MA) and ligated with amplified 
PCR fragments digested with the same enzymes. Ligated vectors were transformed into 
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electrocompetent XL1-Blue cells, and clones were sequenced to verify successful 
transformations. Plasmid DNA was then isolated from transformed XL1-Blue cells, and 
re-electroporated into BL21 cells for protein production. BL21 cell stocks were grown in 
10mL overnight cultures in 2YT + 100µg/mL Ampicillin, 37°C in incubator, and 
transferred to 1L cultures until OD600 reaches 0.8-1. Cells were induced to produce 
recombinant protein by IPTG and cultured for an additional 4 hours. Cells were pelleted 
by centrifugation, resuspended in PBS with complete proteases inhibitor tablet (Roche 
applied sciences, Indianapolis IN) and lysed by addition of lysozyme and sonication. Lysed 
product was filtered and run on a GST column (HiTrap GSTPrep, GE Lifescience, 
Pittsburg, PA) using an AKTAFPLC liquid chromatography system (GE Lifescience, 
Pittsburg, PA). Products was digested with thrombin overnight to cleave GST tag, and 
purified Fn fragments were separated from cleaved products by purification with GST 
column in series with Benzamidine column (HiTrap Benzamidine FF, GE Lifescience). 
Purified Fn fragments were checked for purity by SDS-PAGE and western blotting.  
 
Phage displaying panning using Tomlinson I+J and human domain antibody libraries 
(dAb)  
 Fn fragments (FnIII9*10, FnIII9-4G-10) were coated on Nunc MaxiSorp plates 
(Thermo Fisher Scientific, Pittsburg, PA), (10µg/well, 40 wells per Fn fragment) overnight 
at 4°C. Next day, the plates were aspirated, and blocked with 2% milk in PBS for 1 hours 
to block against non-specific binding. Tomlinson I+J and human domain antibody (dAb) 
library (Geneservice, United Kingdom) phage pannings were performed in parallel. Phage 
were incubated on plates for 1 hour, and supernatant phage was collected by aspiration. To 
deplete binding of phages selected on FnIII9*10 fragment for binding to the FnIII9-4G-10 
fragment, the plates were incubated with soluble Fn fragments (soluble FnIII9*10 fragments 
incubated on FnIII9-4G-10 coated plates, and visa versa), for 1 hour. Plates were then washed 
with PBST 3 times, and bound phage eluted by incubation with 1mg/mL trypsin in PBS 
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for 1 hour. Eluted phage were infected into freshly grown Tg1 E.Coli. cells from an 
overnight grown culture, and grown on 2YT + 4% glucose + 100µg/mL ampicillin plates 
overnight. After overnight growth on the plates, colonies were scraped off the plates and 
pooled to create cell stocks. To produce phage for the next round of panning, aliquots of 
phage-infected cell stocks were grown overnight and induced to produce phage by co-
infection with KM13 helper phage, and phage purified by PEG/NaCl precipitation. Three 
rounds of phage panning was performed.   
 
ELISA assay for specific binding scFv antibodies 
 After scFv phage pannings were completed on Fn fragments, individual scFv 
antibody clones were picked into wells of a 96-well plate, with 2YT + 4% glucose + 
100µg/mL ampicillin and grown overnight at 37°C in shaker incubator. Next day, a fresh 
plate was inoculated with 5µL of overnight cultures and grown for additional 3 hours. Cells 
were pelleted by centrifugation, resuspended in 2YT + 0.1% glucose + 100µg/mL 
ampicillin, and 1mM IPTG to produce scFv antibodies for 16 hours at 25°C, 220rpm in 
incubator. ELISA plates were coated with antigen (FnIII9*10 on one half of plate, FnIII9-4G-
10 on the other half) overnight at 4°C, and blocked with 2% milk in PBS for 2 hours at room 
temperature. Blocking solution was aspirated, and scFv antibodies were incubated in 
duplicates on left and right halves of the ELISA at room temperature for 1 hour. Wells 
were washed 3 times with PBST, and primary anti-Myc biotin antibody was incubated for 
1 hour at room temperature. Well of the plate were washed 3 times with PBST, and 
secondary antibody (Extravidin HRP) was incubated for 1 hour at room temperature. Plates 
were washed 3 times with PBST, and 2 times with PBS. One-step Ultra ELISA TMB 
substrate (65µL) was incubated in the wells, until a deep blue color develops. The reaction 
was stopped by addition of 40µL of 2N sulphuric acid, and OD at 450nm was recorded 
using a multiwell plate spectrophotometer. Analysis of ELISA signal for each scFv 
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antibody was performed by the ratio of the signal from the FnIII9-4G-10 well over ratio from 
the FnIII9*10 well.  
    
scFv antibody production in HB2151 cells 
 Clones identified from scFv ELISA assay were streaked out on TAG plates. For 
each scFv to purify, 20mL of 2YT + 4% glucose + 100µg/mL ampicillin was inoculated 
with a single colony and grown for 4 hours at 37°C, 220rpm in incubator. To each culture, 
2x1011 KM13 helper phage was added, and incubated for 1 hour at 37°C water bath. 
Infected cells were pelleted by centrifugation, and resuspended in 50mL of 2YT + 0.1% 
glucose + 100µg/mL ampicillin and 50µg/mL kanamycin. Cultures were grown at 25°C, 
220rpm in incubator for 20 hours to produce phage. Phages were purified by PEG/NaCl 
precipitation and infected into fresh HB2151 E.Coli. cells grown mid log-phase growth, 
OD600 0.4, and incubated for 30mins in a 37°C water bath. Infected HB2151 cells were 
pelleted by centrifugation, resuspended in 0.5ml of 2YT, and plated out onto TAG plates 
to grow overnight at 37°C. After overnight growth, cells were scrapped off the plates, and 
frozen cells stocks were created by addition of 20% glycerol, to be stored at -80°C. One 
vial of frozen stock of scFv producing HB2151 cells was added to 1L of 2YT + 0.1% 
glucose + 100µg/mL ampicillin, and grown at 37°C, 220rpm for until OD600 reaches 0.8. 
To the culture, IPTG was added to a final concentration of 1mM to induced scFv antibody 
expression, and grown overnight at 25°C, 220rpm in the incubator. Overnight cultures were 
centrifuged to pellet the cells, and supernatant containing the soluble scFv antibodies were 
filtered using a 0.22µm filter. Filtered media was run over a HiTrap ProteinA column (GE 
Lifescience, Pittsburg, PA) using an AKTA FPLC liquid chromatography system. Purified 
scFv antibodies were separated into aliquots, lyophilized, and stored at -20°C. Purity of the 
purified scFv was checked SDS-PAGE and WB.  
 
scFv antibody labeling with Alexa Fluor 546 and Alexa Fluor 750  
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 One milligram (1mg) of purified scFv antibodies was used per labeling reaction. 
To each reaction, 20X mole excess of TCEP was added to reduce disulfide bonds within 
the scFv antibodies, and 10X mole excess of the dye, either Alexa Fluor 546 C5 maleimide 
or Alexa Fluor 750 C5 maleimide was reacted for 4 hours at room temperature. Unreacted 
dye was removed by extensive dialysis against PBS. Degree of labeling was calculated 










Where 𝐴𝑥 is the absorbance values at absorption maximum wavelength, and 𝜖 is the molar 
extinction coefficient of the dye. 𝐴𝑥 = 93,000 at 556nm for Alexa Fluor 546, and 𝐴𝑥 = 
290,000 at 753nm for Alexa Fluor 750. Tomlinson I+J scFv antibodies have MW of 
approximately 30kDa, while dAb scFv antibodies have MW of 17kDa.  
 
Epitope mapping of scFv antibodies with competitive ELISA 
 ELISA plates were coated with the Fn fragment that the scFv antibodies was 
isolated against (FnIII9*10 or FnIII9-4G-10) overnight at 4°C, and blocked with 2% milk in 
PBS for 2 hours at room temperature. The wells were then aspirated, and the scFv antibody 
of interest was co-incubated with soluble FnIII6-9, FnIII10-14, FnIII9*10, or FnIII9-4G-10 in a 
dose dependent manner (from 0.1µg/mL up to 100µg/mL) for 1 hour at room temperature. 
Wells were washed 3 times with PBST, and primary anti-Myc biotin antibody was 
incubated for 1 hour at room temperature. Well were washed 3 times with PBST, and 
secondary antibody (Extravidin HRP) was incubated for 1 hour at room temperature. Plates 
were washed 3 times with PBST, and 2 times with PBS. One-step Ultra ELISA TMB 
substrate (65µL) was incubated in the wells, until a deep blue color develops. The reaction 
was stopped by addition of 40µL of 2N sulphuric acid, and OD at 450nm was recorded 
using a multiwell plate spectrophotometer. Analysis of dose dependent inhibition of scFv 
binding due to competitive binding of soluble Fn fragments was performed by 3 parameter 
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non-linear regression curve fit using GraphPad Prism software, and IC50 inhibition values 
were calculated.  
 
Cell attachment assay with scFv antibodies  
 This assay was developed based on a published protocol for quantitative analysis 
of cell-substrate adhesions(90). Wells of a 96-well tissue culture plate was coated with Fn 
(10µg/ml) in PBS overnight at 4°C. Wells of the plate was then blocked with 200uL of 
10mg/mL heat denatured BSA solution for 1 hour, at room temperature. Cells of interest 
were then prepared at a concentration of 2 X 105 cells/mL for HFF, 7.5 X 105 cells/mL for 
H69 cells, 6 X 105 cells/mL for CHOB2 and CHOB2-αvβ3 cells, and 1 X 106 cells/mL for 
K562 cells. To estimate 100% cell attachment, dilutions of 5%, 10%, 20%, 50%, and 100% 
of the working concentrations of cells were prepared and added to uncoated, unblocked 
wells. For assays using β1 integrin blocking antibodies, an aliquot of the cell suspension at 
twice the working concentration was mixed with the β1 mAb at 30µg/mL. To test the effect 
of the scFv antibody, 50µL of the scFv antibody was added to the appropriate wells, 
incubated for 5mins at 37°C, and 50µL of cell suspension was added the wells. The plate 
was incubated for 20min (HFF) or for 1 hour (other cell types) at 37°C, with the lid 
removed. Wells used for estimating 100% cell attachment was fixed by adding 100µL per 
well of 5% glutaraldehyde. Experimental well were washed gently 3 times with PBS, using 
cut-off pipette tips, and fixed for 20mins with 100µL of 5% glutaraldehyde. Wells were 
washed 3 times with deionized water, and 100µL of 0.1% (w/v) crystal violet was added 
to each well. After overnight staining, wells were washed 3 times with 400µL of deionized 
water, crystal violet was solubilized with 10% (w/v) acetic acid, and absorbance at 590nm 
was recorded using a multiwell plate spectrophotometer. Data from 5%, 10%, 20%, 50%, 
and 100% attachment wells were used to determine the value for 100% attachment by 
linear regression curve fitting, and experimental data was expressed as a percentage of 
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input cells attached. Statistical analysis was performed using one-way ANOVA with 
Tukey’s post-test.  
 
Integrin cell surface staining and flow cytometry analysis 
 Cells (HFF, CHOB2, CHOB2-αVβ3, and K562) were harvested and resuspended 
at a concentration of 5x106 cells/mL in ice-cold FACS buffer (PBS, 10% FBS, 0.1% 
sodium azide). One hundred microliters (100µL) was used for each staining condition. 
Cells were stained with the appropriate antibody at manufacturers suggested dilutions for 
30min on ice. Cells were then washed with ice-cold PBS by centrifugation at 1500rpm for 
5min three times, then resuspended in 100µL ice cold FACS buffer. Staining with 
secondary antibodies, or isotype control antibodies, were performed on ice and incubated 
for 30mins in the dark. Cells were then washed with ice-cold PBS by centrifugation at 
1500rpm for 5min three times, then resuspended in 200µL ice cold FACS buffer and stored 
for analysis the same day. For storage longer than 16 hours, the cells were resuspended in 
200µL of ice cold 4% formaldehyde for 10mins, then resuspended in 200µL ice cold PBS. 
Flow cytometry was performed on an Accuri C6 flow cytometer (BD Biosciences, San 
Jose, CA). At least 50,000 events was recorded per group.  Data analysis was performed 
using FlowJo software, gating on the isotype controls.  
 
Spinning disk cell adhesion strength assay 
 Assays of the effects of scFv antibodies on adhesion strength of fibroblasts to Fn 
was tested with the help of Dr. Imen Hannachi (ME, GaTech) following a similar published 
protocol(91). Glass coverslips (25mm diameter) were treated with oxygen plasma and 
coated with 10ug/ml of Fn in PBS overnight. Fn was then aspirated, and coverslips were 
blocked with 10mg/mL heat denatured BSA for 1 hour at room temperature. scFv 
antibodies or HFN7.1 antibodies were incubated on the coverslips for 1 hour at room 
temperature, then coverslips were washed 3 times and stored in PBS for use the same day. 
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Fibroblasts (HFF) were seeded at 125,000cells/cm2 and allowed to attach for 2 hours at 
37°C. Coverslips were spun on a spinning disk apparatus as described in (91), attached 
cells were fixed with 4% paraformaldehyde, and stained with DAPI. Imaging of the 
attached cells was performed, and image analysis was performed using home developed 
MATLAB script to plot adhesion fraction as function of shear stress (Garcia Lab, GaTech). 
Experimental points were fit to a sigmoid to obtain the τ50 value, or shear stress at 50% 
detachment of cells. Statistical analysis was performed using one-way ANOVA with 
Tukey’s post-test. 
 
SPR analysis of scFv antibodies binding to Fn fragments 
 A self-assembled monolayer of alkanethiols comprised of 20% -COOH and 80% -
OH functional groups (Prochimia, Poland) was assembled on a BIACORE gold sensor chip 
surface, by incubation of 1mM stock alkanethiol solution on the gold chip overnight at 
room temperature. SPR experiments were performed on a BIACORE 2000 instrument. Fn 
fragments in immobilization buffer (0.1M sodium acetate, pH 4.5) were immobilized on 
the chip using EDC/sulfo-NHS chemistry, and unreacted –COOH was quenched by 
injections of 1M ethanolamine, pH 9. Dilutions of scFv antibodies were prepared in binding 
buffer (10mM HEPES, 150mM NaCl, 0.0001% Triton-X 100, pH 7.4) in concentrations 
ranging from 0.5µg/mL to 120µg/mL, and injected over the chip surface using kinetic 
injections at 30µL/min, with a 10min dissociation time. Regeneration of surface was 
performed using two injections of 5µL each of regeneration buffer (20mM EDTA, 1M 
NaCl, pH 6). SPR sensograms were processed with Scrubber2 software for double 
referencing, and curves were fit to experimental data using a 2-site heterogeneous surface 
model using ClampXP software.    
 
Results 
Isolation of scFv antibodies selected against stabilized Fn fragments 
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 Engineered Fn fragments spanning the 9th and 10th type III repeats of Fn were 
produced as reported(51), in which a Leu1408Pro mutation was created to stabilize the 
spatial orientation of the synergy site (PHSRN) in III9 with respect to the RGD site in III10 
(stabilized mutant - FnIII9*10). In native Fn, the synergy site is approximately 3.5nm away 
from the RGD loop, and its precise spatial location and orientation is thought to be critical 
for mediating high affinity α5β1 integrin engagement(92, 93). An increase in this 
separation distance could then perhaps serve as an extracellular matrix cue to guide 
differential cell-integrin engagement and mediate a different cell response.  
 
Figure 9. ELISA assay for selection of scFv antibodies following phage panning 
on Fn fragments. Individual scFv antibodies was produced and incubated on both 
FnIII9*10 and FnIII9-4G-10. Ratio of ELISA signal was used as a metric to assess scFv 
antibodies with skewed preference in binding one Fn fragment over the other.  
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 To this end, engineered Fn fragments mimicking the extension of III9 and III10 
repeats were created by insertion of 4 glycine residues in the linker region between III9 and 
III10 (Figure 8). This was created to model the increase in the separation distance between 
the synergy site in the 9th type III repeat and the RGD loop in the 10th type III repeat and 
may arise from mechanical loading of the Fn molecule along a fiber. Molecular 
visualizations in PyMol software suggested that this 4 glycine insertion increased the 
separation distance between the PHSRN and RGD sites to an average of 4.3nm. These 
fragments were produced recombinantly in BL21 E. Coli cells and purified using an 
AKTAFPLC liquid chromatography system.  
 Phage display and selection using human single fold (scFv) antibody has distinct 
advantages over peptide phage display, including higher binding affinities, ease of addition 
Table 2. scFv antibodies identified by ELISA following selection on Fn 
fragments 
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of epitope tags, and inducible expression and purification of soluble antibodies. The scFv 
antibodies libraries that we chose to utilize in phage pannings was developed by Greg 
Winter’s and co-workers by incorporating diversity at human framework VH (domain 
antibody library – dAb)(94) or VH and VΚ (Tomlinson I+J library)(95). Large libraries 
could be generated, with diversities estimated at 1.47 x 108 for Tomlinson I, 1.37 x 108 for 
Tomlinson J, and 3 x 109 for the dAb antibody library.  
Thus, by performing phage display and selection using these scFv antibody libraries 
on recombinant Fn fragments mimicking molecular tension in FnIII9-10 domains, we could 
isolate specific antibodies with high binding affinities against a known portion of Fn that 
mediate specific ECM-integrin interactions.  
Following phage display panning and selection, we developed an ELISA assay 
(Figure 9) to select scFv antibodies with differential targeting selectivity towards the 
stabilized FnIII9*10 mutant versus the 4 glycine insertion mutant (FnIII9-4G-10). This ELISA 
detected the Myc tag that was present on the scFv antibodies - and by analyzing the ratio 
of the relative ELISA signal of each individual antibody on binding to FnIII9*10 vs. FnIII9-
4G-10, conformational specific antibodies could be isolated. This ELISA assay identified 40 
clones (Table 2), of which preliminary sequencing identified 11 unique scFv antibodies 
(Table 3). Cell stocks of these antibodies were then created in HB2151 E. Coli production 
cells, and purified using an AKTA FPLC liquid chromatography system.  
 
Table 3. Translated sequences of selected scFv antibodies 
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 A competitive ELISA assay was developed to localize the binding epitope for the 
purified scFv antibodies of interest. To establish whether the binding epitope of each scFv 
is within the 9th, 10th, or spans both Fn type III repeats: soluble Fn fragments including 
either the 9th type III repeat alone (FnIII6-9), or the 10
th type III repeat alone (FnIII10-14) 
were co-incubated with scFv antibodies on ELISA plates adsorbed with the FnII9-10 
fragments to which the scFv was selected against. By varying the concentration of soluble 
Fn fragments in a dose dependent manner, if the epitope that the scFv antibody recognized 
is also found within the soluble Fn fragments, then a dose-dependent inhibition of scFv 
antibody binding to the adsorbed Fn fragments is expected. This inhibition could be 
quantitatively determined using standard non-linear regression analysis, and IC50 values 
could be determined for each scFv antibody for which inhibition of ELISA signal was 
observed. Of the scFv antibodies tested (Figure 10), H5 and G8 scFv antibody binding 
were found to be effectively inhibited by soluble Fn fragments containing the 9th type III 
Figure 10. Epitope mapping of scFv antibodies by competitive ELISA. A) Competitive binding of 
soluble FnIII6-9 and FnIII10-14 with H5 antibody, on ELISA plate coated with FnIII9-4G-10, B) 
competitive binding of soluble FnIII6-9 and FnIII10-14 with G8 antibody, on ELISA plate coated with 
FnIII9-4G-10, C) competitive binding of FnIII6-9 and FnIII9-4G-14 with F8 antibody, on ELISA plate 
coated with FnIII9-4G-10 
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repeat (Figure 10A-B), F8 scFv antibody binding was only inhibited by soluble Fn 
fragments including both the 9th and 10th type III repeats  (Figure 10C).  
 
 Binding kinetics of scFv antibodies to Fn fragments were evaluated using SPR. Fn 
fragments (100µg/mL) were immobilized using EDC/sulfo-NHS chemistry, and kinetic 
binding experiments were performed using kinetic injections of the scFv antibodies 
analyte, with a 10min dissociation phase following each injection. Sensograms for each 
scFv antibody was double referenced using Scrubber2 software against both blank 
injections as well as to a blank sensor surface. Modeling and curve fitting was done in 
ClampXP software, using a heterogeneous surface model. Equilibrium dissociation 
constants for each scFv was determined to be the following: (Figure 11A) A4 scFv 
antibody: 659µM for binding to FnIII9*10, 249µM for binding to FnIII9-4G-10, (Figure 11B) 
H5 scFv: 107nM for binding to FnIII9*10, 16nM for binding to FnIII9-4G-10, (Figure 11C) 
Figure 11. SPR sensograms of scFv antibodies on Fn fragments mimicking molecular tension in 9th 
and 10th type III repeats. Simulations are shown in red, while experimental datasets are shown in 
black.  Insets show residuals for simulations. Fn fragment immobilized to SPR chip is indicated on each plot. 
A) A4 scFv, B) F8 scFv, C) H5 scFv, D) G8 scFv.   
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F8 scFv: 9.73µM for binding to FnIII9*10, 14.75µM for binding to FnIII9-4G-10, (Figure 
11D) G8 scFv: 76nM for binding to FnIII9*10, 56nM for binding to FnIII9-4G-10. 
In addition, we performed SPR analysis using Fn fragments containing either the 
9th, or 10th type III repeats to further confirm and localize the binding epitopes for the 
selected scFv antibodies. Results suggested that the epitope for the A4 antibody binds 
within the 10th type III repeat (Figure 12A), H5 and G8 antibody binds within the 9th type 
III repeat (Figure 12C, D), and that the F8 antibody binds an epitope spanning both the 9th 
and 10th type III repeats (Figure 12B). Together, these results confirmed and were 
consistent with the observed results from the competitive ELISA assays (Figure 10).  
 
Inhibition of cell attachment to Fn by scFv antibodies 
Following phage display pannings and selection by ELISA assay, isolated and purified 
scFv antibodies were assessed in a functional assay in which the ability to modulate and 
inhibit cell attachment to Fn was tested. In an initial assay with a panel of 4 scFv antibodies, 
only the H5 clone was found to functionally inhibit attachment of human foreskin 
fibroblasts (HFF) to Fn. Incubation of HFF with H5 reduced attachment to Fn to 
Figure 12. SPR sensograms of scFv antibodies on 9th or 10th Fn type III repeats. Simulations are 
shown in red, while experimental datasets are shown in black.  Insets show residuals for simulations. 
A) A4 scFv antibody, B) F8 scFv antibody, C) H5 scFv antibody, D) G8 scFv antibody 
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approximately 55% (Figure 13). Incubations of HFF cells with a function blocking 
antibody against β1 integrins reduced cell attachment to about 23%, and incubation of both 
β1 mAb and H5 antibody reduced cell attachment to 11%, though the difference was not 
statistically significant at a p-value of 0.05 (Figure 13).   
 In another model cell line of H69 small cell carcinoma cells, which express 
primarily α3β1 (laminin, Fn) and small amounts of α6β1 integrins (laminin), we found that 
H5 scFv did not significantly affect H69 cell attachment, and that inhibition using a β1 
integrin mAb did not significantly block cell attachment, suggesting that in these cells β1 
integrins are not the primary integrin used to attach to Fn. (Figure 14).  
Figure 13. Modulation of HFF cell attachment to Fn by scFv antibodies. HFF cells (20,000 cells/well) 
were seeded on Fn (3µg/mL) and assayed for attachment in the presence of H5, and an anti-integrin β1 
antibody. At least six replicates were used per sample, error bars are SEM. (statistics performed using one 
way ANOVA with Tukey’s post-test *, p<0.05, ***, P<0.001) 
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The additive effects of both the β1 mAb and H5 scFv antibody in inhibition of cell 
attachment in human foreskin fibroblasts led us to hypothesize that H5 may be inhibiting 
another integrin receptor in addition to α5β1 integrins. The CHO-B2 cell line(96), a mutant 
variant of the popular Chinese hamster ovary (CHO) cells deficient in integrin α5β1, was 
chosen as an a model cell line to test this hypothesis.  
CHO-B2-αvβ3 cells stably expressing integrin αvβ3 was created by transfection of 
the parent CHO-B2 cells with the appropriate plasmids and selection by flow cytometry. 
Assessing modulation of cell attachment by the H5 antibody in these cells revealed that 
Figure 14. Inhibition of H69 cell attachment to Fn by H5 scFv and β1 mAb.  H69 cells (250,000 
cells/well) were seeded on Fn (3µg/mL) and assayed for attachment in the presence of H5, and an anti-
integrin β1 antibody. At least six replicates were used per sample, error bars are SEM. (statistics 
performed using one way ANOVA with Tukey’s post-test *, p<0.05) 
 
 45 
incubation of H5 antibody with the CHO-B2-αvβ3 cells completely blocked αvβ3 based 
cell attachment and reduced attachment levels to the same as the parent CHO-B2 cell line 
(Figure 15). To assess integrin α5β1 dominated attachment, we chose to use the K562 cell 
line (97). These cells were derived from a myelogenous leukemia origin, and do not express 
αV or β3 integrins (98, 99). The K562 cells only expressed α5β1 integrins, and also free 
Figure 15. Modulation of CHO cell attachment to Fn by H5 scFv antibody. CHO cell variants 
(10,000 cells/well) were seeded on Fn (3µg/mL) and assayed for attachment in the presence of H5, and 
an anti-integrin β1 antibody. At least six replicates were used per sample, error bars are SEM. (statistics 
performed using one way ANOVA with Tukey’s post-test *, p<0.05, ***, p<0.001) 
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β1 integrins not associated with α5(100). Furthermore, these cells required a β1 activating 
antibody(101) for switching to high affinity integrin conformations. Incubation of H5 with 
the β1 activated K562 cells reduced cell attachment to Fn by approximately 30% (Figure 
16), and this effect was abolished by blocking β1 integrins on the cell surface with an anti- 
β1 function blocking antibody. Together, these data suggested that the H5 antibody has 
selectivity in completely blocking integrin αvβ3-Fn interactions, and only moderately 
inhibited integrin α5β1-Fn interactions.  
 
 
Discussion and Conclusions 
 We used engineered Fn fragments of the FnIII9-10 region to model the molecular 
scale conformational spacing between the PHSRN and RGD sites with the Fn central cell 
binding domain. By performing phage display and selection using antibody libraries, we 
isolated scFv antibodies that demonstrated specificity in binding to the two model Fn 
fragments in an ELISA assay. Furthermore, the H5 antibody clone, which preferentially 
targeted to FnIII9-4G-10, was found to be particular effective in blocking Fn-integrin αVβ3 
interactions. 
 By epitope mapping studies, the binding epitope of the H5 antibody was localized 
to within the 9th Fn type III repeat. It was then surprising to find that H5 is effective for 
blocking binding of integrin αVβ3 to Fn, which binds to the RGD loop in the 10th Fn type 
III repeat. It is possible that binding of H5 to Fn could cause steric inhibition of the 
neighboring RGD site and thus prevent integrin αVβ3 binding. The finding that integrin 
α5β1 was still able partially bind to Fn in the presence of H5 could be attributed to its very 
high binding affinity (4nM) to Fn(102) when compared to binding affinity of αVβ3 to 
Fn(103) (affinity of αVβ3 to RGD: 1.3uM), or perhaps by differences in the conformational 
fit of the integrin headpieces when bound to Fn between integrin α5β1 versus αVβ3. More 
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likely, however, is that the insertion of the 4 glycine mutations results in a conformational 
tilt between the 9th and 10th Fn type III repeats, and studies have suggested that this 
interdomain tilt angle can regulate both αvβ3 and α5β1 integrin binding to the FnIII9-10 
region(104).  
 The selectivity of the H5 antibody in completely inhibiting integrin αVβ3-Fn 
interactions, but only moderately inhibiting integrin α5β1-Fn interactions could 
theoretically allow for H5 to probe the hypothesized “integrin switch” in vivo. The utility 
Figure 16. Modulation of K562 attachment to Fn by H5. K562 cells (50,000 cells/well) were seeded on 
Fn (3µg/mL) and assayed for attachment in the presence of H5, and an anti-integrin β1 antibody. At least 
six replicates were used per sample, error bars are SEM. (statistics performed using one way ANOVA with 
Tukey’s post-test ***, p<0.001) 
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of our molecular probes developed against Fn for imaging of Fn was evaluated in a number 




CHARACTERIZATION OF ENGINEERED MOLECULAR PROBES 
FOR IMAGING OF FN IN VITRO AND IN VIVO 
 
 The mechanical properties of the ECM has emerged as a critical factor in regulating 
cell adhesion (105), migration (106), and fate decisions (107). Moreover, the mechanics of 
the ECM in native tissues and within tumors microenvironments may be important in 
controlling and/or promoting transformation and metastases (106, 108, 109). At the cellular 
scale, topographic features in the ECM that are sensitive to mechanical forces may regulate 
receptor recognition, resulting in reorganization of cytoskeletal structure and altering cell 
migration and invasion – a phenomenon that has been well studied in vitro(44).  
 Despite these important roles of ECM mechanics in regulating cell and tissue 
function, there are currently no direct methods to image the ECM and provide information 
on the mechanics of the matrix in a non-invasive manner. Thus, opportunities exist to 
develop imaging probes that can be sensitive to mechanically-induced conformational 
changes to ECM proteins. Development of such ECM targeted probes would have 
applications for diagnosis and targeted therapeutics for tissue engineering and regenerative 
medicine, as well as enabling fundamental ECM mechanobiology research.  
 The phage-peptide probes and antibody probes we developed in Chapter 3 and 4 
have demonstrated ability to discriminate between Fn of varying molecular conformations. 
In this chapter, we describe the methods we used to characterize these molecular probes 
for imaging of Fn in a number of model systems in vitro, as well as in vivo for minimally-
invasive imaging of Fn within the lung parenchyma of mice in a bleomycin-induced model 






 The probes were fluorescently labeled with Alexa Fluor dyes for 
immunofluorescence imaging, and probe staining was evaluated in three types of in vitro 
model systems of Fn. First, the probes were characterized for their staining on in vitro Fn 
fibers of varying strain, using the same method of Fn fiber generation as in Chapter 3. 
Semi-quantitative analysis of the captured fluorescence images were performed by 
calculating the ratio of the probe staining normalized to the Fn within the Fn fibers. Next, 
fibroblasts were used to assemble an ECM in culture, and fluorescent staining of the probes 
were evaluated and qualitatively assessed, with and without the use of pharmacologic cell 
contractility inhibitors. In addition, lung tissue sections were prepared from mouse lungs, 
and similar analysis of fluorescent staining using the phage-peptide probes and antibody 
probes were performed. Finally, the H5 antibody was labeled with a near-infrared 
fluorescent dye, and evaluated for ability to image Fn in a live animal (mouse) model of 
bleomycin induced pulmonary fibrosis.  
 
Materials and Methods 
Staining of labeled phage or scFv antibodies on cell assembled ECMs 
 Coverslips (10mm diameter) were sterilized in 70% ethanol and placed into wells 
of a 24-well plate, coverslips were coated with Fn (3µg/mL) overnight at 4°C. Prior to cell 
seeding, the coverslip were washed 3X with PBS and mouse primary lung fibroblasts were 
seeded at 10,000cells/well. Cell were allowed to attach for 30mins at 37°C in the incubator. 
After cells have attached, medium was then aspirated and replaced with medium containing 
1µg/mL Alexa Fluor 488 labeled Fn. Cells were then cultured for an additional 48 hours, 
at 37°C, 5% CO2 in the incubator. In conditions with TGF-β, medium was then to medium 
containing 1µg/mL Alexa Fluor 488 Fn, and 10ng/mL TGF-β 16 hours before fixing cells. 
In conditions where Y-27632 was added, 1µM Y-27632 was added 1 hour before fixing 
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cells. Cells were washed 3X with PBS, and fixed in 4% formaldehyde for 20min. Cells 
were washed again 3X time PBS, with 5min per wash. Fixed cells were blocked for non-
specific binding with 3% BSA in PBS, overnight at 4°C. Labeled phage (1012 CFU/mL) or 
scFv antibodies were incubated for 1 hour, at room temperature, washed 3X in PBST, and 
coverslips were transferred to glass slides, mounted in Prolong gold antifade reagent 
(Invitrogen, Life Technologies, Grand Island, NY), and sealed with a top coverslip and nail 
polish.  
 
Mouse bleomycin model of IPF 
C57/BL6 mice (female, 6-8 weeks age) were anesthetized using a 
ketamine/xylazine/acepromazine cocktail, and injected with Bleomycin sulfate(Enzo life 
science, Farmingdale, NY) at a dose of 3.2U/kg through intratracheal injections. Injection 
volumes were 50µL of solution, with additional 10µL of air bolus. Immediately after 
injection, mice were placed on heating pads and allowed to recover from anesthesia before 
placed back into housing.  
 
Figure 17. Bleomycin model of mouse pulmonary fibrosis. Bleomycin (3.2U/kg) was injected intra-
tracheally into C57/Bl6 female mice of approximately 8 weeks old. This mouse model of fibrosis results in 
rapid fibrotic response approximately 1 week after bleomycin induction. After approximately 1 month, 
fibrosis resolves spontaneously..  
 
 52 
Lung isolation and tissue sectioning 
 At set time points after bleomycin injections, mice were euthanized and the lungs 
were collected. Mice were anesthetized by injections with 
ketamine/xylazine/acepromazine cocktail (50µL/animal), and toe pinch was used as a 
metric to make sure the mice were not responsive. Mice were taped down by the limbs and 
cleaned by wiping with an ethanol wipe. Using a scissor, a small cut was made near the top 
of the chest cavity, and the trachea was isolated using tweezers. A nylon string was fed 
through below the trachea, and a small cut was made in the trachea near the top, and a 
trachea tube was inserted into the trachea. PBS (500µL) was injected slowly through the 
trachea tube to lavage the lung, aspirate and repeat. The nylon string was tied off to close 
the trachea. A patch of skin was cut and the internal organs of the mouse was exposed: the 
renal arteries were cut to exsanguinate the mouse. A gauze pad was used to soak up the 
blood. A cut was made vertically, all the way up to trachea tube and through the rib cage, 
cut slightly off center to avoid cutting the trachea. Both sides of the rib cage was clipped 
with hemostat and pried apart, exposing the lungs and heart. The heart was pulled down 
with tweezers, and a small cut was made in the right ventricle in the orientation aligned 
with the pulmonary valve. A blunted 30 gauge needle and syringe was inserted into the 
right ventricle, with the aim of insertion into the pulmonary valve, and 1mL of PBS was 
injected to perfuse the lungs. The lungs and heart were removed from the rib cage by 
careful cutting away from the chest cavity by pulling up on the nylon string and cutting 
away the surround tissue. The lungs and heart were placed on a ringstand with tubing, and 
fixed with 4% paraformaldehyde in PBS by gravity. The fixed tissue was stored in 4% 
paraformaldehyde at 4°C until sample processing and tissue slicing.  
 
Cryo-section preparations and immunofluorescence staining of lung samples 
 Fixed lungs were placed into 20% sucrose overnight at 4°C. Samples were placed 
into cryomolds with O.C.T. compound (Electron Microscopy Sciences, Hatfield, PA). 
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Using liquid N2, 1-methylbutane was frozen solid in a plastic container, and the cryomolds 
were frozen by placing into direct contact with the frozen 1-methylbutane and placed into 
a -20°C freezer overnight. Next day, frozen sections (10µm thickness) were prepared on a 
Cryostar NX70 cryostat (Thermo Scientific, Pittsburg, PA) and transferred to Plus-glass 
slides. Slides were stored at -80°C.  
 Lung sections were blocked overnight at 4°C with 3% BSA in PBS. All staining 
was performed by sandwiching the staining solution (150µL per slide) between the slide 
and a parafilm surface. Primary scFv antibody (H5) was incubated at 10µg/mL for 1 hour 
at room temperature. Slides were washed in PBST, 3 times for 5 minutes each. Anti-myc 
antibody was incubated on slides at 1:1000 dilution for 1 hour at room temperature. Slides 
were washed in PBST, 3 times for 5 minutes each. Secondary antibody (Alexa 546 goat 
anti-mouse, 1:2000 dilution) was incubated on slides for 1 hour at room temperature, 
followed by washing in PBST, 3 times for 5 minutes each. Slides were mounted in Prolong 
Gold antifade reagent, sealed with nail polish, and stored at -20°C until imaged.   
 
IVIS imaging with scFv antibodies 
 Mice (C57/BL6, female, 8 weeks old, Charles River Laboratories, Wilmington, 
MA) were anesthetized using Ketamine/xylazine/acepromazine cocktail, and hair on chest 
area was removed by shaving and Nair® hair remover. Alexa Fluor 750 labeled scFv 
antibodies were injected into the lateral tail vein (50µg per injection). Mice were imaged 
on IVIS Lumina® imaging system (Xenogen) using the following parameters: excitation: 
745nm, emission, 780nm, exposure 10 seconds, medium binning, field stop: 2, stage 
position C. Images were acquired with fluorescence efficiencies and acquired at time points 
up to 40mins following injection.  
 
FMT imaging with scFv antibodies  
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 Mice (C57/BL6, female) were anesthetized by isofluorane inhalation, and hair on 
chest and back was removed by shaving and Nair® hair remover. Alexa Fluor 750 labeled 
scFv antibodies were injected into the lateral tail vein (50µg per injection). Mice were 
imaged on FMT 2000 fluorescence tomography system (Perkin Elmer). Scans were 
acquired at pre-injection, and at time points (5min, 10min, 15min, 20min, 30min, 40min) 
post-injection to monitoring accumulation and clearance of the antibody to and from the 
lungs.  
Results 
Immunofluorescence staining of phage probes on Fn in model systems 
 To directly image phage probe targeting to Fn fibers under varying strain, we used 
a semi-quantitative approach using fluorescently labeled phage and normalization to 
fluorescently labeled Fn within the fibers.  Phage binding to Fn fibers deposited on 
micropatterned PDMS substrates was assessed on increasingly strained Fn fibers ( = 0.9 
to 2.6; Figure 18a). Fluorescence intensity of the Fn fiber at 633nm (AF633-labeled phage) 
Figure 18.  Staining of specific phage clones correlate with Fn fiber strain. Phage clones displaying the 
LNLPHG and RFSAFY peptides were labeled with AlexaFluor 633 SE and incubated on Fn fibers (1 X 
1011 phage per sample). A) Staining of labeled LNLPHG phage decreases with increasing fiber strain, and 
staining of RFSAFY phage increases with increasing fiber strain. B) i-xii) Fluorescence images of labeled 
phage clones on Fn fibers under varying strain. LNLPHG phage binding to relaxed ( = 0.93) (i,ii) and  
strained (=2.64) Fn fibers (iii,iv). RFSAFY phage binding to relaxed ( = 0.93)(v,vi) and strained 
(=2.64)Fn fibers (vii,viii). Labeled control phage show minimal binding (ix-xii). Error bars are SD. All 
images acquired with 63X oil immersion objective, scale bar is 20 m.  
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was normalized to the amount of Fn in the fiber (5% AF488-labeled tracer Fn). The Fn 
fibers labeled with the LNLPHG clone showed a nonlinear but reproducible decrease in 
fluorescence signal as strain increased (Figure 18bi-iv). Conversely, as expected, Fn fibers 
labeled with the RFSAFY clone showed an increased signal with fiber strain (Figure 18b, 
v-viii).  The intensity of  Fn fiber labeled with a control (random) phage was negligible 
(non-detectable) at all strains tested (Figure 18bix-xii). Targeting selectivity for the 
LNLPHG clone, defined as [signal at λ=0.9]/[signal at λ=2.6], was determined to be 7.29. 
Targeting selectivity for the RFSAFY clone, defined as [signal at λ=2.6]/[signal at λ=0.9] 
was determined to be 3.13. 
 As a result of combining phage display screening with control over Fn fiber strain, 
we discovered relatively simple probes that are capable of detecting varying states of strain 
in Fn fibers.  Importantly, our approach does not require the Fn to be chemically labeled (a 
requirement and limitation of the FRET method).  Such probes enable the interrogation of 
native Fn ECM, allowing us to address a critical gap in the determination of the relevance 
Figure 19. Staining of specific phage clones on cell assembled ECM. Phage clones displaying the 
LNLPHG and RFSAFY peptide motifs were labeled with Alexa Fluor 633 SE and incubated on ECM 
assembled by primary lung fibroblasts (1 X 1011 phage per sample). Experiments performed with and 
without the ROCK inhibitor Y27632 to relax the matrix top left, Staining of LNLPHG phage observed 
primarily on large diameter fibers, and increased after matrix relaxation top right, Staining of RFSAFY phage 
observed primarily on large diameter fibers. Staining is minimal after matrix relaxation by Y27632. Bottom, 




of force-mediated Fn structural modifications.  As a first demonstration of this principle, 
we used our phage clones to discriminate fibers within native cell-assembled Fn.  Fn was 
assembled by contractile primary lung fibroblasts cultured in the presence of tracer Fn 
(AF488-labeled; Figure 19). Labeled (AF633) phage clones were detectable primarily 
within larger diameter fibers and their binding was highly correlated with cell-mediated 
tensional strain of the Fn ECM as demonstrated by the addition of the cellular contraction 
inhibitor, Rho-kinase inhibitor Y-27632. Specifically, staining of native, cell-derived Fn 
fibers with the LNLPHG phage was non-detectable at steady state and increased upon 
addition of Y-27632, which results in a more relaxed (lower strain) Fn ECM (Figure 19 
a,b,c,d), and decreased upon stimulation of cell contraction with TGF-β(Figure 19e,f).  
Concomitantly, staining of native, cell-derived Fn fibers with the RFSAFY phage clone 
Figure 20: Staining of specific phage clones on prepared living lung slices. a-d) co-staining of multiple 
Fn targeting probes on a representative mouse lung slice. (a) staining of polyclonal anti-mouse Fn 
antibody, (b) staining of labeled RFSAFY phage, detected with AF633.e-g) staining of labeled random 
phage clone detected with AF546. h-j) staining of labeled random phage clone detected with AF633. k) 
representative phase micrograph of a prepared living lung slice. Images in panel a-j acquired with 63X oil 
immersion objective. Scalebars, a-j) 20m, k) 100m. 
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demonstrated robust staining at steady state and significantly decreased upon Y-27632 
addition (Figure 19 g,h,i,j), but was not changed with TGF-β stimulation (Figure 19 k,l).  
Staining of Fn fibers with a labeled control phage was non-detectable with or without Y-
27632 or TGF-β treatment further demonstrating the specificity of the peptide-strain 
specific antigen interaction (Figure 19 m-r).  
As a further proof of concept demonstration, mouse living lung slices were prepared 
(Figure 20k), and staining of our phage clones were evaluated in concert with a 
commercially available anti-Fn antibody (Figure 20).  
 Qualitatively, our phage probes were able to delineate Fn matrix morphology, 
similar to the staining patterns of the Fn-antibody (Figure 20 a-d). Interestingly, the 
staining of RFSAFY phage (Figure 20b) appeared more punctuate and appeared to be 
more spatially heterogeneous when compare to the staining of Fn antibody (Figure 20a). 
Additionally, labeled control phages displayed no detectable binding regardless of labeling 
species (Figure 20 e-j). In addition, co-incubation with an excess of a polyclonal anti-Fn 
antibody were able to inhibit binding of both phage probes (Figure 21). Similar results 
were obtained using a molecular probe approach (Figure 22).  Specifically, quantum dot-
peptide conjugated probes displaying either LNLPHG or RFSAFY peptides similarly co-
Figure 21. Competitive binding of polyclonal anti-Fn antibody displaces binding of phage probes on 
tissue lung slices. A polyclonal anti-Fn antibody (1mg/mL) was titrated in along with the LNLPHG phage 
and RFSAFY phage at 1:1000 (a, b, g, h), 1:100 (c, d, i, j), and 1:10 (e, f, k, l) dilutions. Images acquired 
with 63X oil immersion objective. Scale bar is 20µm. 
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stained with a polyclonal Fn antibody (Figure 22, a-f). Further, no staining was observed 
for the scrambled versions of both molecular probes (Figure 22, g-j). 
 
  
Figure 22. Staining of labeled peptides on prepared living lung slices. Peptides corresponding displayed 
peptides on phage-based probes were generated by solid phase synthesis and contain a C-terminal cysteine for 
chemical ligation (peptides: LNLPHGGGC, RFSAFYGGC, HLNPGLGGC, AYSRFFGGC). Peptides were 
conjugated to Qdot© and purified per manufacturer’s instructions (Molecular Probes). (a-c) staining of 
LNLPHG-probe and co-staining with polyclonal anti-Fn antibody (d-f) staining of RFSAFY-probe and co-
staining with polyclonal anti-Fn antibody. g-h) staining of scrambled LNLPHG probe. i-j) staining of 
scrambled RFSAFY probe. All images acquired with 63X oil immersion objective. Scale bar is 20µm.  
 
 59 
Immunofluorescence staining of scFv antibodies of Fn in model systems 
On in vitro Fn fibers 
Purified scFv antibodies were assessed for their utility in immunofluorescence 
staining of in vitro deposited Fn fibers (Figure 23). Specifically, staining of the A4 scFv 
(Figure 23, a) and F8 scFv (Figure 23, b) both showed a negative correlation with 
increasing strain in Fn fibers, while the H5 scFv antibody (Figure 23, c) showed increased 
staining with increased Fn fiber strain, with robust staining along Fn fibers at fiber strains 




Figure 23. Immunofluorescence staining of scFv antibodies correlate with Fn fiber strain. Fn fibers 
were deposited on PDMS membranes and strained to defined amounts. At least 6 fibers were analyzed per 
sample. Error bars are SEM. Statistics performed with one-way ANOVA, with Tukey’s post-test, (*, 
p<0.05, **, p< 0.01, ***, p<0.001, ****, p<0.0001.) 
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Figure 25. Immunofluorescence staining of H5 on cell assembled ECMs. Primary mouse lung 
fibroblasts were cultured to assemble an ECM containing Fn. Total Fn was visualized by incorporation of 
Alexa 488 Fn into the Fn matrix. Fn staining is shown in green. Scalebar is 20µm.  
Figure 24. Mechano-sensitive staining of H5 antibody on Fn fibers in vitro. Fn fibers were deposited on 
PDMS membranes and strained to defined amounts. At least 6 fibers were analyzed per sample. Error bars 
are SEM. Statistics performed with one-way ANOVA, with Tukey’s post-test, (*, p<0.05, **, p< 0.01, ***, 
p<0.001, ****, p<0.0001.) 
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On Fn fibers within cell assembled ECMs 
Figure 25. Immunofluorescence staining of H5 on cell assembled ECMs. A) Primary 
mouse lung fibroblasts were cultured to assemble an ECM containing Fn. Total Fn was 
visualized by incorporation of Alexa 488 Fn into the Fn matrix. Fn staining is shown in 
green. Pierson correlation coefficient (R) is shown as indicated. B) Quantitation of 
ratiometric images from panel A. Scalebar is 20µm.  
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 In ECMs assembled by cultured mouse primary fibroblasts, the H5 antibody can be 
used to fluorescently image Fn within this matrix (Figure 25). Notably, the staining of the 
H5 antibody do not completely co-localize with fluorescently labeled Fn assembled into 
the matrix (Pierson correlation coefficient R = 0.70) – suggesting that H5 is likely 
discriminating between Fn molecules of different conformations within the matrix. 
  Blebbistatin (20µM) was added to cultures to inhibit cell contractility and relax the 
matrix, in which case a slight reduction in overall H5 staining intensity was observed. In 
cultures where TGF-β (5ng/mL) was added to stimulate cell contractility and induce 
fibroblasts to exert greater forces on their ECMs, the H5 staining patterns were markedly 
pronounced when overlaid with the Fn signal, and appears to be able to delineate specific 
regions along distinct Fn fibers within the matrix (arrowheads), as well as discriminate 
among Fn fibers. Moreover, quantitative ratiometric image analysis (dividing the H5 signal 
over the Fn signal) revealed spatially distinct patterns of H5 antibody staining within the 
ECM, and overall H5 targeting to Fn (as measured by global H5/Fn intensity) was 
dependent on cell contractile phenotype. The TGF-β cultures stained most prominently for 
H5, followed by the untreated cells, and the blebbistatin treated cells with the least amount 






On ex vivo mouse lung tissue slices from normal and fibrotic mice 
 Frozen tissue sections were generated from lungs of normal and bleomycin-induced 
fibrotic mice, and staining of H5 was assessed on these samples (Figure 26). By 
immunofluorescence, the H5 staining pattern localized to fibrillar Fn within the ECM 
(Pierson correlation coefficient R = 0.86, normal, and R = 0.73, fibrotic). Furthermore, 
ratiometric image analysis revealed that the H5 staining patterns within these lung samples 
were spatially distinct (assayed using a polyclonal anti-Fn antibody) – again suggesting 
distinct conformational states of Fn within the matrix.  Furthermore, the staining of a 
labeled control scFv antibody was minimal on both fibroblast assembled ECMs and frozen 
tissue sections of both normal and fibrosis mouse lungs (Figure 27). 
  
Figure 26. Staining of H5 on lung tissue samples from normal and fibrotic mice.  Immunofluorescence 
staining of H5 on frozen lung tissue slices. In merged image, DNA is shown in blue, Fn is shown in green, 
and H5 is shown in red. Pierson correlation coefficient (R) is shown as indicated. Scalebar is 20µm.  
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Figure 27. Minimal staining of a negative control scFv antibody. A negative control antibody was 
produced from a random clone from the parental Tomlinson I library, and staining experiments were 




Minimally invasive imaging of Fn using H5 in live animals 
 Purified H5 antibody was labeled with Alexa Fluor 750 fluorescent dye and used 
to image the Fn within the lung interstitium of anesthetized mice. Labeled H5 antibody was 
introduced by tail vein injection, and accumulation in the lung interstitium was monitored 
using small animal bioimaging systems. In preliminary experiments using a Xenogen 
Lumina® IVIS system, the fluorescence of the Alexa 750 labeled H5 antibody was 
monitored following tail vein injection into both normal and bleomycin induced fibrotic 
mice. Fluorescence signal appeared to accumulate in the lungs to above background levels 
approximately 5 minutes post-injection (Figure 28), and all fluorescence was undetectable 
at approximately 1 hour post-injection, usually following urination by the animal.  
 
 Fluorescence intensity was qualitatively similar between normal and fibrotic mice. 
However, using a much more sensitive 3D fluorescence molecular tomography (FMT) 
imaging system, differences in accumulation of fluorescently labeled H5 was distinctly 
Figure 28. IVIS imaging of normal and fibrotic mice by tail vein injection. Alexa 750 
labeled H5 was injected via tail vein and imaged at indicated time points post-injection. 
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discernible between normal and fibrotic mice (Figure 29). H5 accumulated in both the left 
and right lungs, and maximal difference in accumulation between normal and fibrotic mice 
occurred at 10mins following injection, subsequent quantitative analysis showed a 
difference in total fluorescence of 84.99 (normal, arbitrary units) vs. 745.75 (fibrotic, 
arbitrary units)  
 
 To rule out non-specific accumulation in the lungs, an Alexa 750 labeled negative 
control scFv antibody was similar injected, and accumulation in the lungs was minimal 
(Figure 30).  
 In preliminary studies to monitor the kinetics of antibody circulation in vivo, it was 
observed that injected antibodies were rapid cleared via kidneys. At approximately 40 
minutes following tail vein injection, most of the injected antibodies were accumulated in 
the kidneys (Figure 31) as monitored by FMT. By approximately 1 hour after injection, 
Figure 29. Accumulation of Alexa 750 labeled H5 antibody in lungs of normal and 
fibrotic mice by tail vein injection. Fibrotic mice was imaged 1 week after bleomycin 
injection. FMT images were acquired at approximately 10 minutes after injection. 
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antibodies were secreted by urination, although weak residual fluorescence could still be 
detected 24 hours in the lungs following a single injection of H5.  
 
  
Figure 30. Minimal accumulation of control scFv antibody in mouse lungs. Alexa 
750 labeled negative control scFv antibody was injected into control and fibrotic mice via 
tail vein injections, and imaged via FMT. Accumulation in control mouse: 6.44 AU, 




Monitoring fibrotic resolution using the H5 antibody 
Using Immunofluorescence and Histology 
 Lungs were harvested from bleomycin injected animals at set time points (1, 2, 4, 
8, and 10 weeks). Lung sections were embedded in OCT and frozen sections were 
generated for staining. By immunofluorescence staining with the H5 antibody, and 
corresponding H&E staining of serial sections (Figure 32), it was observed that maximal 
fibrosis was observed at the 1 week time point, and coincided with maximal H5 staining. 
As this time point, lung tissue morphology was significantly disrupted, as imaged with 
H&E staining. Increases in cell numbers was observed, with increased matrix deposition, 
and reductions in airway space. This is characteristic of the bleomycin model, and likely 
represented a combination of fibrosis and inflammatory responses. 





Figure 31. Rapid clearance of injected scFv antibodies via kidneys. One single 
injection of Alexa 750 H5 antibody was introduced via tail vein, and fluorescence was 
monitored via FMT. Scans shown in perspective to better delineate anatomy.  
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 Over the subsequent weeks, the architecture of the lungs returned to normal. By 8 
weeks, histological sections of the lungs appeared similar to control (saline) sections. The 
staining of the H5 antibody mirrored the histological observations of fibrosis progression. 
At the 1 week time point, prominent staining of H5 observed, which decreased in staining 
and was similar to staining on control (saline) sections by the 8 week time point.  
 
  
Figure 32. Resolution of fibrosis monitored by H5 in an in vivo model of mouse 
pulmonary fibrosis. Mouse lungs were harvested at the isolated time points following 
bleomycin injection, and frozen tissue sections were generated. A, C, E) Tissue sections 
were immunostained for H5 (red), Fn(green) and DNA (blue). B, D, F) H&E staining of a 




Using In vivo FMT imaging 
 The H5 antibody was labeled with Alexa 750, and in vivo imaging using FMT was 
performed at 1, 2, 4, and 8 week time points (Figure 33) to monitor progression and 
resolution of fibrosis. In contrast to the gradual resolution observed histologically, imaging 
by FMT using the H5 antibody revealed that excluding the 1 week time point, scans from 
the other time points were very similar. This may be attributed to vascular remodeling after 




Fibrotic – 1 week Fibrotic – 2 weeks Fibrotic – 4 week 
Fibrotic – 6 week Fibrotic – 8 week control 
Figure 33. Monitoring of fibrotic resolution by FMT imaging. At set time points 
indicated, Alexa 750 H5 antibody was injected via tail  vein, and accumulation in the 
lungs was monitored by FMT. 
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Discussion and Conclusions 
 
 The H5 antibody’s ability to image Fn within the ECM was assessed in a number 
of in vitro model systems. Using in vitro generated Fn fibers deposited on PDMS 
membranes, we found that the staining of the H5 antibody, when normalized to the total 
amount of Fn within each fiber, increased in accordance to increasing fiber strain. 
Additionally, the H5 antibody was also able to fluorescently stain Fn fibers in a more 
physiologically relevant system of fibroblast-assembled ECMs, whereby staining of H5 
correlated with pharmacological perturbations of cell contractility. Thus, the H5 antibody 
appears to be sensitive to mechanical alterations to Fn fibers, within more strained fibers 
resulting in higher staining The H5 antibody was also tested on ex-vivo lung samples from 
both normal and bleomycin-injured fibrotic mice, where we observed more pronounced 
staining of H5 on fibrotic lung sample. Part of the enhanced staining could be attributed to 
more Fn present in the fibrotic tissue regions, and this was confirmed by probing with a 
polyclonal anti-Fn antibody. However, co-staining with both the polyclonal anti-Fn 
antibody and the H5 antibody revealed that H5 was spatially heterogeneous in its staining 
of Fn within the matrix, with distinct regions of high H5 staining not localized with the 
polyclonal Fn antibody – further suggesting that H5 is recognizing a specific conformation 
of Fn within the ECM.  
 In preliminary studies, the utility of the H5 antibody for in vivo diagnosis of fibrosis 
was assessed in a mouse model of bleomycin-induced pulmonary fibrosis. At the time point 
associated with maximal Fn deposition as assessed by histology (1 week following 
bleomycin injection), in vivo imaging of accumulated H5 antibody in the lungs revealed 
that the H5 antibody was able to distinguish between control(saline) mice versus 
bleomycin-injured mice, with a (>4 fold difference) higher accumulation in lungs of 
bleomycin-injured mice. With further improvements and optimizations to selectivity of the 
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H5 antibody, one can envision using simple threshold image analysis for processing of 
clinical images for early detection of fibrosis.  
 We assessed the potential of the H5 antibody for use in monitoring fibrotic 
resolution over time. Over a period of 10 weeks, histological sections revealed that the 
mice graduated recovered without treatment, as expected of the single-dose intra-tracheal 
bleomycin model. By the 10 week time point, lung architecture, cellularity, and matrix 
straining was qualitatively very similar to uninjured controls. Additionally, the H5 
antibody staining levels was also similar to staining levels on tissue samples from control 
uninjured mice. Together, these results suggested that the H5 antibody could be useful as 
an imaging probe to detect early stages of fibrogenesis, and its staining levels can be 
correlated to fibrotic resolution.  
We were less successful in using FMT with the H5 antibody to track fibrosis resolution 
over time minimally invasively in vivo (Figure 33). We observed a rapid increase in H5 
accumulation in the lungs at the 1 week time point, and lower accumulations at all other 
time points. This may be attributed to vascular damage and remodeling following the 
bleomycin injection, which may limit transport of the H5 antibody from the blood at these 
later time points. Future investigations may explore alternative models of fibrosis without 









The role of mechanical forces in mediating cell-ECM interactions is becoming 
increasingly important in understanding how the ECM directs cell behavior and cell fate. 
In particular, forces emanating from contractile cells such as pathogenic myofibroblasts 
have been hypothesized to partially unfold ECM proteins like Fn, thus 
engaging/disengaging theorized integrin “switches”(110) and perhaps be one cause in the 
pathogenesis of idiopathic pulmonary fibrosis(64). Despite considerable in silico and in 
vitro evidence for the extensibility of Fn within fibers and Fn type III domain unfolding (6, 
16, 18) there is still no direct evidence that such molecular events occur in vivo, a fact that 
perpetuates the debate regarding the physiological relevance of such observations. We 
found that we could generate in vitro Fn fibers, apply mechanic strain, and observe a 
Figure 34. Staining of phage probes is specific and cannot be displaced by BSA. A) AF633 
labeled LNLPHG phage were incubated on Fn fibers of λ = 0.9 at the indicated concentrations 
for 1 hour. B) AF633 labeled LNLPHG phage were incubated on Fn fibers of λ = 0.9 at the 
indicated concentrations for 1 hour. C-D) the indicated phage were co-incubated with 
increasing concentrations of BSA on Fn fibers for 1 hour.  
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concomitant correlation between fiber strain with the exposure of cryptic cysteine residues, 
consistent with literature reports(111). Furthermore, our lab has also shown that 
recombinant Fn fragments could be generated to mimic the conformational states of the 
Fn9-10 type III repeats, and demonstrated a role in directing integrin specificity(51). 
However, questions remained on whether these biophysical conformational changes to the 
Fn exists within native ECMs in vivo, and furthermore whether these conformational 
changes could be exploited as molecular targets for study. 
Figure 35. Co-staining of phage probes with Beta 1 integrin subunit and vinculin on fibroblast cultures. 
a-d) Staining of LNLPHG phage with Beta1 integrin subunit. e-h) staining of RFSAFY phage and Beta 1 
integrin subunit. i-l) staining of LNLPHG phage and vinculin. m-p) staining of RFSAFY phage and vinculin.  
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  These questions led us to develop platform technologies to isolate conformation-
specific molecular probes to Fn: both for Fn fibers, as well as to engineered Fn type III 
repeat fragments. Using a peptide phage display library, we isolate two phage clones 
displaying the peptides LNLPHG and RFSAFY that targeting to Fn fibers under relaxed 
and strained conditions, respectively.  
 The two peptides display highly reproducible binding characteristics to Fn fibers: 
with increasing (decreasing) strain, LNLPHG binding is reduced (increased) and RFSAFY 
binding is increased (reduced).  Therefore these two probes can be used in concert to 
achieve exceptionally high resolution of the strain state of Fn fibers through cross 
comparison of their binding to the same fiber (e.g., Figure 20), assuming no steric 
hindrance between the two probes.  Most importantly, these peptide-based probes are 
Figure 36. Integrin expression of human foreskin fibroblasts. At least 
50000 events were recorded for each sample. Fluorescence was gated on 
IgG isotype controls.  
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capable of discriminating native Fn fibers, enabling the detection of Fn fiber strain events 
in vivo. 
 Even with the selectivity of each identified probe in detecting and discriminating 
Fn fibers of variable strain, the specific epitopes on Fn fibers to which these probes are 
targeting cannot be determined with the present system. Indeed, this is not a trivial matter 
since the structure and molecular packing of Fn fibers themselves have not been elucidated.  
The fibrillogenesis process is known to involve self-association of Fn molecules through 
integrin-mediated mechanically-exposed cryptic polymerization sites (3) yet recent 
evidence suggests as many as 8 different Fn-Fn interactions can occur further complicating 
a basic understanding of Fn fiber arrangement(8). Thus under force, the extensibility of Fn 
fibers may be due to a combination of rearrangement of Fn-Fn interactions within the fiber, 
rearrangement of the heterotypic type III domain interactions within a single Fn 
molecule(18), or unfolding of Fn type III domains (70). Any of these events could 
Figure 37. Integrin expression of CHO cell lines. A) CHOB2 cells, B) CHOB2-αvβ3 cells. At least 50000 
events were recorded for each sample. Fluorescence was gated on IgG isotype controls. 
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potentially create new epitopes that can be targeted by the phage.  Additionally, recent 
evidence suggests that Fn fibers become fouling, i.e. exhibit significant non-specific and 
presumably hydrophobic protein-protein interactions, upon straining(76).  However, our 
data suggest that this non-specific fouling effect does not contribute significantly to the 
observed specific binding of our probes, as we observe saturable binding of our probes 
with increasing concentrations (Figure 34 A, C). Furthermore, at the saturation point, 
incubations with increasing amounts of BSA (Figure 34, B, D) did not significantly affect 
either probe signal, suggesting that it was not capable of competing for specific binding to 
fibers with our probes. Additionally, we do not observe significant levels of nonspecific 
staining of the relaxed fiber-specific probe (or the control phage) on strained fibers. Co-
staining of both phage probes with the fibrillar adhesion marker integrin beta-1 and the 
focal adhesion marker vinculin did not appear to show significant differential phage 
accumulation at sites of adhesion (Figure 35), suggesting that the epitope targeted by the 
phage probes is likely along the entire length of the Fn fiber, and not localized at sites of 
Fn- adhesion linkages.  
 Building upon techniques that we have used in working with Fn fibers, we then 
performed phage display using antibody libraries and selection on Fn fragments spanning 
the 9th and 10th type III repeats to isolate Fn conformation specific antibodies. The approach 
of isolating conformation-specific antibodies by phage display is not unique, as recent work 
by Lefkowitz and coworkers have used phage display to isolate a conformation specific 
Fab to activated β-arrestin-1(112). Likewise, we have used a similar approach, by using 
phage display to isolate conformation-specific antibodies to the FnIII9-10 region, in 
support of detecting molecular signatures of the hypothesized integrin switch. 
 Using phage display, we isolated and identified one particular scFv antibody – the H5 
antibody, that was found to have mechano-sensitive immunofluorescence staining of Fn in 
multiple model systems (in vitro fibers, assembled ECMs in culture, ex vivo tissue 
samples), but with more robust staining compared to the earlier peptide phage probes 
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isolated on Fn fibers, possibly due to the higher affinities of the antibody probes versus the 
peptide phage probes. Furthermore, the H5 antibody was also found be functionally 
capable of modulating the attachment of cells to Fn by selectively blocking Fn-integrin 
αvβ3 interactions – suggesting perhaps detection of the long sought after “integrin-switch”.  
In cell attachment assays using human foreskin fibroblasts (HFFs), co-incubation of the 
cells with H5 reduced the cell attachment to 59% compared to cells without H5 (Figure 
13). Incubation with a function blocking antibody against β1 integrins in these cells 
reduced attachment to 30% even without H5 antibody, but H5 antibody together with 
function blocking antibody against β1 integrins together further reduced cell attachment to 
11% of control levels. These results suggested that H5 was likely inhibiting the interactions 
of other integrin(s) besides β1 integrins, or that it may have broader inhibitory effects on 
multiple Fn integrins, that included β1 integrin among other integrins that was express by 
HFFs. However, HFF express a number of integrin receptors on the cell surface, including 
α2, α6, α5β1, αVβ3, among others (Figure 36), and thus it was difficult to establish which 
integrin-Fn interaction(s) the H5 antibody specifically inhibits.  
 For this reason, we looked at cell lines that expressed a more restricted set of integrins.  
We first investigated the H69 human small cell lung carcinoma cells (Figure 14), which 
expressed predominantly α3β1 integrins and moderate amounts of α6β1 (113). These 
integrins bind primarily laminin, but α3β1 also has reported binding to Fn and 
collagen(113). We observed no significant inhibition of cell attachment with H5 incubation 
(reduction of attachment from 42% without H5 to 35% with H5). In these cells, incubation 
with the β1 integrin function blocking antibody had no statistical effect on attachment to 
Fn (with β1 mAb: 30.9% attachment, without: 42% attachment). For comparison, the 
background level of attachment to BSA blocked tissue culture wells was 27%. Together, 
these results suggested that H69 cells do not attach strongly to Fn, and furthermore integrin 
α3β1 was not the primary integrin mediating this attachment to Fn. The H69 cells have also 
reported to express αV mRNA as well as small amounts of the protein (114), and this may 
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be one way in which these cells mediate binding to Fn in the presence by β1 integrin 
binding antibodies, as integrin αvβ1 can also function as a low affinity fibronectin 
receptor(115). However, this does not seem to be the target of the H5 antibody’s inhibitory 
effects, as incubation of H5 had no statistical effect on attachment levels.  
In order to isolate the integrin specific inhibitory effects of the H5 antibody, we chose to 
test inhibition of cell attachment in other engineered cell lines: the CHOB2 cell line, along 
with the CHOB2 cells stably transfected with integrin αvβ3. The CHOB2 cell line was 
developed as a mutant of the popular Chinese hamster ovary cell line (CHO), in which 
CHOB2 cells were distinguished by the lack of α5, αV, and β3 integrin subunits(115). By 
flow cytometry, it was verified that CHOB2 cells lacked all relevant integrins, and stably 
transfected CHOB2-αvβ3 cells expressed integrin αvβ3 at high levels (Figure 37). In 
CHOB2 cells stably transfected with integrin αvβ3 (Figure 15), we observed that 
incubation with the H5 antibody reduced cell attachment from 51.7% to 22.7%, similar to 
attachment levels of the CHOB2 parent cell line (22.5%), suggesting robust and complete 
abrogation of attachment by the H5 antibody. 
 In another cell line, the K562 leukemia line, which expressed only integrin α5β1 at 
appreciable levels (Figure 38), we observed that the H5 antibody reduced cell attachment 
by 30% (Figure 16), and that this effect was abolished by blocking antibodies against β1. 
Together, these results suggested that the H5 antibody inhibits cell attachment to Fn by 
Figure 38. Integrin expression of K562 cells. At least 50000 events were recorded for each sample. 
Fluorescence was gated on IgG isotype controls. 
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primarily interfering with Fn-integrin αvβ3 interactions, and also partially interfering with 
Fn-integrin of α5β1 interactions.  
 The mechano-sensitive targeting of H5 to Fn was supported by the data from a 
number of experiments that we have conducted. After phage panning and selection, we 
performed an ELISA assay of binding of scFv antibodies against both adsorbed FnIII9*10 
and FnIII9-4G-10 fragments, from which we discovered that the H5 antibody preferred bound 
to the FnIII9-4G-10   by a factor of approximately 2. In addition, in analyzing the binding 
kinetics of H5 antibody to both of these Fn fragments using surface plasmon resonance 
(SPR), the binding affinity of H5 to the FnIII9-4G-10 fragment was found to be approximately 
6.7 times stronger (Figure 11) compared to binding to the FnIII9*10 fragment (KD = 16nM 
on FnIII9-4G-10    versus KD = 107nM on FnIII9*10). Together, these results confirm that H5 
binds the FnIII9-4G-10 fragment, which mimics a “strained” conformation of the Fn, with 
higher affinity. This observation was translated also to Fn fibers, in which we observed that 
indeed Fn fibers of higher strain show much higher staining intensities of the H5 antibody 
compared to Fn fibers of low strain. Indeed, the approach of isolating conformation-
specific antibodies by phage display is not unique, as recent work by Lefkowitz and 
coworkers have used phage display to isolate a conformation specific Fab to activated β-
arrestin-1.24 Likewise, we have used a similar approach in this paper, using phage display 
to isolate conformation-specific antibodies to the FnIII9-10 region, in support of detecting 
molecular signatures of the hypothesized integrin switch. 
 The utility of the H5 antibody in mechano-sensitive imaging of Fn was assessed in 
a number model systems. Most directly, using Fn fibers deposited on PDMS membranes 
of defined strain (Figure 24), normalized fluorescence staining of H5 increased with 
increasing fiber strain: with little staining on relaxed fibers, and pronounced staining of the 
fibers at higher strains. Notably, staining was not uniform along the length of the fibers, 
and seemed punctate in nature – suggesting perhaps differences in conformations of the 9-
10th Fn type III repeats along the length of the fiber. Moreover, in ECMs assembled by 
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fibroblasts in culture, the H5 antibody was also able to distinctly stain Fn fibers within the 
ECM (Figure 25). The staining patterns of H5, while specific to Fn fibers, did not 
completely overlap with fluorescently labeled tracer Fn that was incorporated into the Fn 
matrix. This suggested that the H5 antibody was able to discern Fn molecules that were of 
a different conformation, and not otherwise observable by simply staining against Fn. 
Furthermore, H5 staining greatly increased following TGF-β stimulation of the fibroblasts, 
which induced cell contractility and increased ECM deposition. However, after brief 
exposure to TGF-β (overnight), the amount of Fn deposited and assembled into the ECM 
is not significantly more compared to unstimulated cells. Likely, the Fn already assembled 
into fibers within the matrix may be under more tension, as these fibroblasts have been 
induced to exert higher contractile force on their ECMs. Indeed, the enhanced staining of 
H5 may be suggestive of this ECM signature, in which increased H5 staining may suggest 
an increase in the conformational epitope for H5 between the 9-10th Fn III domain in these 
TGF-β stimulated cultures.   
 We then tested the H5 antibody on lung tissue samples from normal and fibrotic 
mice in a bleomycin-induced model of pulmonary fibrosis (Figure 26). From 
immunofluorescence studies on frozen lung tissue slices, we observed that the slices from 
the fibrotic lungs contained more Fn within the interstitium when compared to tissue slices 
from normal lungs, indicative of enhanced matrix deposition and ongoing fibrogenesis. 
However, we did observe substantially more H5 staining on fibrotic tissue samples, 
compared to control (non-fibrotic) samples. Furthermore, when the H5 antibody was co-
stained with a polyclonal anti-Fn antibody, we were able to again observe non-complete 
overlapping and co-localization of the two antibodies, again suggesting that H5 is able to 
discern conformational states of Fn that was not otherwise observable using a simple 
antibody stain against Fn. We speculate that regions of high H5 staining maybe be outlining 
regions of “fibroblastic foci”, which are nodules of connective tissue and highly contractile 
myofibroblasts, and is a signature of pulmonary fibrosis in human IPF tissue samples.  
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 To explore the clinical translational potential of the H5 antibody for using in 
minimally invasive diagnosis and monitoring of pulmonary fibrosis, we designed 
experiments using Alexa Fluor 750 labeled H5 antibodies injected via the tail vein in both 
normal and fibrotic mice at one week after bleomycin injury. We then monitored the 
accumulation of H5 in the lung interstitial spaces post-injection. Using fluorescence 
molecular tomography (FMT) imaging, accumulation of H5 was distinctly discernible in 
both lungs, and maximal signal was observed at 10 minutes after injection. Importantly, 
the accumulation of injected H5 in the lungs correlated positively with fibrosis (Figure 
29), with approximately 8.8 times more accumulation in the lungs of fibrotic mice 
compared to normal lungs (745.75 AU vs. 84.99 AU, arbitrary fluorescence units). This 
difference in targeted accumulation in the lungs of fibrotic mice is likely due to 2 main 
reasons: (1), fibrotic lungs contained more Fn within the lung parenchyma and thus more 
of the injected H5 should accumulate simply due to more Fn present in the lungs of fibrotic 
mice, and (2), it is likely that within the lungs of the fibrotic mice, due to myofibroblast 
activation and proliferation, more of the Fn has adopted the molecularly strained 
conformation that the H5 antibody recognized with high affinity. The relative contributions 
of these two causes to the enhanced accumulation of H5 in fibrotic lungs is difficult to 
separate in vivo, and may require multi-modal imaging and normalizing with respect to 
amount of Fn present in both normal and fibrotic lungs. 
 We assessed the potential of the H5 antibody for use in monitoring the resolution 
of fibrosis over time, again using the bleomycin mouse model of fibrosis. We harvested 
lung tissues samples from bleomycin-injected mice at set time points after injury, and 
tracked the progression and resolution of fibrosis on these tissue samples histologically and 
using the H5 antibody in fluorescence imaging (Figure 32). As expected, we observed 
rapid onset of fibrosis and an inflammatory phenotype at the one week time point in the 
lungs. This manifested in increased cellular proliferation, enhanced matrix deposition, 
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reduction in air space, and general disruption of alveolar structure. At this time point, we 
also observed the maximal H5 staining of Fn within the ECM.  
 Over a period of 10 weeks, histological sections revealed that the mice graduated 
recovered without treatment, as expected of the single-dose bleomycin model. By the 8 
week time point, lung architecture, cellularity, and matrix straining was qualitatively very 
similar to uninjured controls. Additionally, the H5 antibody staining levels was also similar 
to staining levels on tissue samples from control uninjured mice. Together, these results 
suggested that the H5 antibody could be useful as an imaging probe to detect early stages 
of fibrogenesis, and its staining levels can be correlated to fibrotic resolution.  
 We were less successful in using FMT with the H5 antibody to track fibrosis 
resolution over time minimally invasively in vivo (Figure 33). We observed a rapid 
increase in H5 accumulation in the lungs at the 1 week time point, and lower accumulations 
at all other time points. This may be attributed to vascular damage and remodeling 
following the bleomycin injection, which may limit transport of the H5 antibody from the 
blood at these later time points. Indeed, this is a limitation of the bleomycin model of mouse 
pulmonary fibrosis. Future investigations may explore alternative models of fibrosis 





 CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Over the past two decades, researchers in the biomaterials, tissue engineering, and 
regenerative medicine communities have come to recognize and fully appreciate the 
importance of the extracellular matrix. This “matrix centered” paradigm has fueled 
numerous research efforts to better understand the complexities of the biochemical and 
biophysical properties of ECMs, with the ultimate goal of harnessing the potential of the 
ECM to control tissue homeostasis, repair/regeneration, and control disease pathogenesis. 
Indeed, significant progress has already been made in these efforts. Decellularized ECMs 
have emerged as one of the most promising scaffolds for tissue engineering in a number of 
organ systems(116-119), and ECM derived from the small-intestine submucosa (SIS) has 
been shown to have potent bioactivities in tissue remodeling and regeneration(120, 121).   
 More recently, researchers have discovered that biophysical changes to the ECM is 
a critical factor during embryogenesis and tissue development, and that mis-regulation of 
such changes may be a contributing cause in many cancers and fibrotic diseases. These 
changes to the ECM can have wide ranging consequences, ranging from changes in binding 
and sequestration of growth factors, conformational alterations in ECM proteins leading to 
changes in matrix architecture, and alterations in presentation of cell-binding motifs. 
Indeed, the importance of ECM mechanics in vivo is consistent with the large collection of 
literature accumulated over the past decades on the effects of substrate rigidity on cultured 
cells. However, directly probing the conformational states of constitute ECM proteins in 
native ECM has been difficult, and has hampered efforts to compare in vitro experimental 
findings to physiology in vivo.  
 In this thesis, I have focused on the ECM protein fibronectin (Fn), and have 
developed mechanically-sensitive targeting probes to both Fn fibers (Chapter 3), and a 
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portion of the 9th Fn type III repeat (Chapter 4). Furthermore, these probes were to be useful 
as imaging probes (Chapter 5) for immunofluorescence imaging of Fn within cultured 
ECMs in vitro, as well as physiologically relevant tissue samples. In addition, the H5 
antibody was also shown to be promising for targeting of Fn in vivo, in a mouse model of 
pulmonary fibrosis.  
 The H5 antibody could be useful as an enabling technology for fundamental cell-
ECM interactions, as well as for translational applications for minimally-invasive imaging 
of the Fn ECM for disease diagnosis and monitoring. Future work using the H5 antibody 
could be to explore the distinct staining pattern observed on Fn fibers, as it may suggest 
that even under uniform strain in a Fn fiber, heterogeneities may exist in the conformation 
of Fn molecules within this fiber. In addition, molecular dynamic simulations focused on 
the linker region between the 9th and 10th Fn type III repeats may help elucidate both the 
epitope of the H5 antibody (likely on the face of 9th type III repeat adjacent to the linker 
region, facing the 10th type III repeat), and the mechanisms by which a 4 glycine insertion 
could alter the stability and equilibrium conformations of this region of Fn.  
 To further characterize the H5 antibody for translational in vivo imaging 
applications, work should be focused on determining the bio-distribution of the H5 
antibody following injection in mice, monitoring accumulation in all relevant organs, and 
determining the clearance times. Additionally, it would be useful to characterize the H5 
antibody on human lung tissue, such as tissue samples from IPF patients, to assess 
clinical relevance of the H5 as a mechano-sensitive antibody for diagnosis of IPF.  
 In collaboration with our colleagues at the University of Michigan (Eric White), 
we will assess the H5 antibody on lung tissue sections obtained via lung cores of normal 
and IPF patients. Immunofluorescence staining will be performed on frozen, 
cryosectioned samples.  Where possible, adjacent sections will be stained with standard 
histochemical stains (H&E, Masson’s, etc.) in order to establish any specificity of the 
probes to particular pathological features.  In preliminary experiments using our 
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candidate H5 antibody, the White lab has demonstrated that H5 antibody is capable of 
binding to fibrillar Fn within human IPF and normal tissue samples. Moving forward, we 
will characterize differences in conformation-sensitive antibody staining in normal vs. 
IPF patient samples, and correlate to histological features such as fibroblastic foci, dense 
fibrosis, and honeycombing.  
 More broadly, we envision that other investigators can take a similar approach to 
develop targeting probes to other ECM fibrillar structures, such as collagen, or fibrin. Such 
developments would open up new avenues of research into the role of ECM mechanics on 
cell and tissue physiology and may have applications such as imaging guided resection of 




DEVELOPMENT OF MAP/DEP TWEEZERS FOR SINGLE 
MOLECULE FN FRAGMENT TWEEZING 
 In our investigations into Fn conformational change under force, we explored 
methods to experimentally manipulate and unfold Fn type III repeats at the single molecule 
scale. Conceptually, we envisioned a platform whereby we can specifically tether 
recombinant proteins of Fn type III repeats to an assay surface at their N-termini, and then 
at their C-termini to polymeric beads. We can then apply forces to these tethered beads on 
a massively parallel scale to unfold the Fn type III repeats. Further, enclosing such a design 
in a microfluidic package would allow for potential integration with biochemical methods 
such as phage display.   
 A number of biophysical methods have been developed more recently to interrogate 
molecular interactions at the micro/nanoscale, including: atomic force spectroscopy(122), 
optical (123) and magnetic (124, 125) tweezers, micropipette based methods(126, 127), 
and dielectrophoresis tweezers(128-130). These methods, while powerful in specific 
applications, have a number of important limitations. Atomic force 
microscopy/spectroscopy and optical tweezers are exquisitely sensitive, but are inherently 
low throughput. The other “tweezer” based methods usually involve applying a force to 
tweeze a biomolecule-tethered microbead, but differ in their methodology of generating 
this force. Importantly, because these methods all utilize a single force to tweeze and 
displace beads, there is no mechanism to move and hold beads at specific equilibrium 
positions. Conceivably, two opposing forces could be used to spatially “tweeze and hold” 
beads at defined positions. Rapid modulation of this position could then make it possible 
to interrogate bead-surface binding interactions with spatial (x, y, and z-axis) and temporal 
(time) control. Furthermore, if this could be realized in a highly parallel format, then one 
could conceivably use controlled bead displacement as a mechanism to develop high 
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throughput platforms for controlled Fn type III repeat unfolding studies, and screening of 
specific biomolecular interactions using methods such as phage display.  
 
Experimental Design 
 To this end, we chose to exploit magnetic (FMAP) and dielectrophoresis (FDEP) as 
the two opposing forces, and demonstrated a proof-of-concept design of such a platform 
by demonstrating the ability to discriminate between specific antibody-antigen interactions 
from non-specific protein-protein interactions.  
Figure 39. Design of combined MAP-DEP bead displacement chip. A) Schematic of chip layout, Nickel 
circular pads (blue) can be magnetized in the presence of an external magnetic field, and were flanked by 
inter-digitated gold electrodes (red). B) Paramagnetic beads were introduced to chip surface by microfluidics 
and loaded onto the magnetic pads, specific antibody-antigen interactions strengthens bead surface tethers. 
C) Interactions probed by application of sufficient DEP force to displace non-specifically loaded beads, but 
not specifically antibody-bound beads. D) Microfabrication process: 1. Grow SiO2 layer on Si substrate, 2. 
Pattern electrodes by EBL, 3. Deposit Ti/Au, 4. Liftoff to create electrode layer, 5. Grow SiO2 to cover 
electrodes, 6. Align and pattern pads by EBL, 7. Deposit Ti/Ni/Au, 8. Liftoff to create magnetic pads layer.  
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 This design could be realized using standard microfabrication processes on an 
insulated silicon substrate. Interdigitated electrodes were used to generate the repulsive 
DEP force, and patterned soft magnetic circular pads were used to generate the attractive 
magnetic force to attract superparamagnetic beads to the surface (Figure 39A).  
Manipulating magnetic beads by the application of a magnetic field is termed 
magnetophoresis(131) and is routinely used in biomedical research for cell separation and 
immunoassays. The net force imparted on a magnetic bead can be calculated in accordance 
with the bead’s magnetic susceptibility χ, volume of the bead V, and the magnetic flux 
density of the field, by the relation  
𝐹𝑀𝐴𝑃 = 𝑉𝜒/𝜇0∇𝐵
2 (132). 
 COMSOL simulations suggested that in the presence of a permanent magnet, the 
nickel pads on the chip surface can be magnetized, with a surface magnetic flux density of 
0.09T. Estimation of the magnitude of FMAP for our design is then approximately 14.2 ± 
0.43pN, as calculated by microfabrication geometries and manufacturer’s parameters of 
the magnetic beads (V = 1.15 *10-17 m3, χ = 192±40).  Commercially available magnetic 
beads (Dynalbeads, Invitrogen) are mostly polystyrene based (>98% by mass), but contain 
embedded superparamagnetic nanoparticles. These beads are thus amenable to 
dielectrophoresis manipulation.  The phenomenon of dielectrophoresis motion arises by 
differential polarization of a dielectric particle within a non-uniform or time varying 
electric field. The net force driving this motion results from the force difference on charges 
at opposing ends of an induced dipole. For a homogeneous sphere(133) of radius r, the time 










where 𝜀𝑚 is the dielectric constant of the medium, and 𝜀𝑝
∗  and 𝜀𝑚
∗  are the complex dielectric 
constants of the particle and medium, respectively. In a time varying electric field, the 
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complex dielectric constant is a function of frequency and the electrical conductivity of the 
material. Thus, depending on properties of the particle vs. the surrounding medium and the 
characteristics of the electric field, the net DEP force can be either positive (pDEP) or 
negative (nDEP). In case of polymeric beads suspended in dilute aqueous buffers and 
sufficiently high AC frequencies, the DEP force will always be negative (nDEP)(128). 
Numerical Simulations suggested that for the designs that we have chosen, both FMAP and 
FDEP in the ranges of 0.3pN to 3pN can be achieved (Figure 40).  
Figure 40.  Numerical simulation of the MAP and nDEP forces on a 2.8µm Dynalbead® imparted by 
the device as a function of its z-axial position. We note that FMAP decreases faster than FnDEP with 
increasing separation of the bead from the device surface. z = 0 is at the magnetic pad surface, z = 1.4 is the 
center of the bead when it sits on the pad surface, and the z value corresponding to the intersections are the 
predicted equilibrium positions of the bead. We show that different magnitude of external magnetic field 
strength and electrical potential can be properly combined to hold the bead at the same z height (e.g., from 
intersection 1 to 2) and displace the bead along z axis (e.g., from intersection 2 to 3). Material properties: 
the magnetic susceptibility of the bead χ = 0.76, the relative permittivity of the bead equals 2.4, the relative 
permittivity of water 80. AC field frequency = 10MHz. 
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Materials and Methods 
Microfabrication 
 Device fabrication was completed on an oxide insulated Si wafer, using a 
combination of E-beam lithography, UV photolithography, and standard evaporation and 
liftoff processes (see Figure 1D for fabrication workflow). Dimensions of magnetic pads 
were 2.5µm in diameter, with 150nm thickness of Ni, and 80nm thickness of Au. Gold 
DEP electrodes were 8µm in length by 2.5µm in width. The chip surface consisted of a 
17x30 array of magnetic pads, flanked by an 18x30 array of interdigitated DEP electrodes. 
The microfluidic flow channel had inner dimensions of 300µm in width, and 20µm in 
height, and was produced in PDMS. Master mold of the microfluidic flow chamber was 
patterned onto a Si wafer using SU-8 photoresist, and the PDMS flow chambers were 
formed by pouring Sylgard 184 (10:1) into molds and curing overnight at 90°C. PDMS 
chambers were aligned and bonded to microfabricated device, and capillary tubing was 
bonded to the inlet/outlet ports of the PDMS channel.  
 
Surface chemistry and bead preparation 
 Oxide surface surrounding magnetic pads was treated by 3-
aminopropyltriethoxysilane, followed by mPEG-NHS (5,000MW) to reduce surface 
adhesion. A self-assembled monolayer (SAM) of alkanethiols (5% -COOH terminated, 
95% -OH terminated) was assembled on the nickel/gold magnetic pads by overnight 
adsorption from a 2mM solution of alkanethiols in ethanol. Recombinant protein fragments 
of fibronectin (FN9-10) was immobilized to the magnetic pads using standard NHS/EDC 
chemistry. Superparamagnetic beads with amine surface functionality (Dynalbeads M-270, 
2.8µm diameter) were prepared per manufacturer’s instructions: 2 x108 beads in 100µL 




 The MAP-DEP device was assembled on microscope stage (Nikon Eclipse Ti) as 
illustrated in (Figure 41), and channels were flushed with deionized water, using a 25µL 
glass syringe driven by a syringe pump (KDS-230, KD Scientific). Superparamagnetic 
beads were diluted 1:10 in 0.1X PBS and injected into the channel at 5µl/min, with rotating 
external magnet to disperse beads and capture single beads to magnetic pads. For DEP 
force generation, electrodes were connected to a function generator (Agilent 33522A), and 
a sinusoidal waveform (10MHz, 10Vpp) was applied.  
 
Results 
 Design of the combined magnetic and dielectrophoresis bead tweezer (Figure 39A) 
consisted of Ni/Au soft magnetic pads flanked by Au electrodes in an arrayed format: (1) 
the Ni/Au pads can be magnetized in the presence of an external magnetic field, generating 
the attractive FMAP force to capture magnetic beads, (2) the interdigitated Au electrodes 
were used to generate the nDEP force used to tweeze captured beads for out-of-plane 
Figure 41. Microscope configuration for imaging and movie capture. 
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displacement. The fabrication procedure (Figure 39D) was such that only the gold on the 
magnetic pads is exposed to solvent, such that relevant biomolecules can be specifically 
Figure 42. Loading and parallel manipulation of beads by MAP and DEP forces. A) Loading of 
paramagnetic beads onto magnetic pads on chip surface. Before beads were injected (left), after loading 
was completed (right), inset, full chip surface showing distribution of beads, scalebar = 50µm. B) 
Coverage and distribution of beads on chip surface optimized by control of external permanent magnet. 
Rotation of magnet (top panel) can minimize multiple beads per pad and, translation of magnet (bottom 
panels) can transport beads and distribute beads over the chip surface. C) DEP force can be used for out-
of-plane manipulation of bead position. In the case of free floating beads near the surface (arrow), turning 
off the DEP force will “snap” the beads to the magnetic pads (top panel). Likewise, beads loaded to the 




immobilized only to the magnetic pad regions using Au-specific chemical coupling 
strategies. Specific protein-protein interactions can then be probed (Figure 39B, C) in 
which weak non-specific bound beads can be displaced by nDEP, while the specifically 
bound beads are more strongly attached and retained.   
 Representative images demonstrating the uniformity of bead loading onto magnetic 
pads (Figure 42) showed that good uniformity of loading can be achieved using only the 
attractive FMAP. The geometry and spacing (2.5µm diameter pad) is very important and 
should closely match the cross sectional area of the bead (2.8µm diameter), as loading 
experiments using 1µm diameter magnetic pads with 2.8µm diameter beads resulted in 
uneven loading and low surface coverage (Figure 43). Furthermore, the rows in the arrays 
of magnetic pads were spaced at a distance less than one bead diameter apart, which helped 
Figure 43. Loading of 2.8µm beads on chips with 1µm pads. Dashed lines show edge of microfluidic channel. 
Scalebar is 50µm. 
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in increasing surface density of the pads as well as helped minimize capturing of multiple 
beads per pad. To further ensure a single bead per pad, rotation of the external magnet can 
be used to “kick-off” any extra beads that may have been loaded onto any single pad 
(Figure 42B). Additionally, translation of the external magnet in the x-y plane can 
transport beads across the magnetic pad array, further improving uniformity in surface 
coverage (Figure 42B).  
 
The DEP force (FDEP) can also be used in conjunction with FMAP to capture beads. For a 
free floating bead close to the surface, turning off the repulsive FDEP can “snap” the bead 
to the magnetic pad, via the attractive FMAP. (Figure 42C, top panels) Conversely, for 
weakly bound beads, applying FDEP can completely dislodge beads (Figure 42, bottom 
panels) and cause them to float away from the plane of focus. Indeed, this is the mechanism 
that we chose to explore in assaying the specificity of protein-protein interactions.    
Figure 44. Specific versus non-specific antibody-antigen interactions probed with bead DEP 
displacement assay. Each data point represents one independent experiment, at least 20 beads were 
analyzed per experiment.  Statistical analysis was performed by t-test, (*, p<0.05) 
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 As a proof-of-principle demonstration of probing a specific protein-protein 
interaction, a model protein (Fn fragment spanning the 9th and 10th type III repeats, FN9-
10) was immobilized to the chip surface by covalent coupling to active groups on a SAM 
layer. The DEP tweezing response of two antibody coated superparamagnetic beads was 
compared (Figure 44).  
  In one group, the beads were conjugated with a specific antibody against FN9-10 
(G8 antibody, binding affinity to FN9-10 with KD = 56nM); in the other group beads were 
conjugated to a control antibody with no binding to FN9-10. At a low level of FN9-10 
protein conjugated to the chip surface (5% active surface), the control antibody coated 
beads were significantly more responsive to DEP displacement when compared to G8 
antibody coated beads (59% median responsive vs. 26% median responsive). However, at 
a high level of protein conjugated to the chip surface (100% active surface), both types of 
beads were more strongly attached and resistant to DEP tweezing. At this high surface 
concentration of FN9-10, the difference in DEP responsiveness between control and G8 
beads was not statistically significant at a p-value of 0.05 (10% median responsive vs. 5.5% 
median responsive). This is likely attributed to non-specific protein-protein interactions, at 
Figure 45. N-terminal modification of Fn fragments by one-step reaction 
and purification with pyridoxal L-phosphate (PLP). A) SDS-PAGE gel of 
purified Fn fragment with incubation of both PLP and Alexa 488 hydrazide 
(left), with Alexa 488 hydrazide alone (middle), or Fn fragments alone (right) B) 
Modified Fn fragment was detected by ketone-specific binding of Alexa 488 
hydrazide.  
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high protein concentrations these may exceed the magnitude of the DEP force needed to 
displace the beads. It is worth noting that a significant but constant fraction (~ 10%) of the 
beads are strongly adhered to the surface, regardless of protein conjugation to chip surface 
or bead-antibody preparation. These strong adhesions to the substrate may be mediated by 
contact forces between topological features on the bead to defects on the chip surface. For 
this reason, optimization of surface chemistries may improve sensitivities of this method 
at high surface protein concentrations.  
 
Discussions and Conclusions 
 We have designed an integrated magnetic and dielectrophoresis based platform for 
nDEP displaced based characterization of specific protein-protein interactions. We used 
soft magnetic pads on the assay chip surface to evenly capture and distribute 
superparamagnetic beads to the fingers of the interdigitated DEP electrodes. We then used 
nDEP to repel and displace beads away from the surface. As a proof of principle 
demonstration, we show the ability to distinguish between specific antibody coated beads 
and control non-specific antibody coated beads, at low surface protein coating densities. 
This platform allows for the potential integration with other bead based immunoassays. 
Furthermore, the magnetic capture, rotation, and bead transport methods described here 
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 In preliminary experiments of applying this system to study unfolding of Fn type 
III repeats, we decided to chemically modify Fn type III repeat fragments to contain a N-
terminal ketone group(134), and used oxime ligation to selectively couple the N-terminus 
of the modified Fn fragments to magnetic beads modified with aminooxy functionality, 
following published reports of specific oxime ligation for coupling proteins(135-142). The 
N-terminal modification of recombinant Fn fragments was successfully completed and 
verified by detection of the ketone functionality (Figure 45).  
 In experiments where recombinant Fn fragments were covalently coupled to an 
activated SAM surface at the C-terminus, and to the superparamagnetic beads via oxime 
chemistry at the N-terminus, we observed that strong adhesion to both the surface and the 
beads (Figure 46) and resistance to movement by DEP. In experimental conditions where 
10% active surface, Fn fragments with N-terminal ketone groups “Fn PLP” and aminooxy 
beads where used, only approximately 10% of the loaded beads responded to a 10V step 
change in DEP force application after 30 minutes of incubation after loading. The strong 
tethering of the beads suggests that the covalent oxime ligation has occurred, but perhaps 
Figure 46. Displacement of Fn fragment-aminooxy beads by DEP. Percentage of magnetic beads loaded 
onto MAP pads that respond to a 10Vpp step change in DEP.  
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the constrained displacement is not detectable with our current microscopy capabilities. In 
addition, confounding factors may also include significant non-specific interactions 
between the Fn fragment coated surface and the beads, as well as likely multiple Fn-
fragment binding to a single bead. Future research may focus on improving microscopy 
methods, such as quantitative imaging by analysis of bead diffraction fringe patterns upon 
z-axial change, and also exploring alternative surface chemistry and coupling strategies 
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